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Abstract
Objectives: To systematically review the effectiveness 
and cost-effectiveness of palivizumab for the prevention 
of respiratory syncytial virus (RSV) in children and 
examine prognostic factors to determine whether 
subgroups can be identified with important differences 
in cost-effectiveness.
Data sources: Bibliographic databases were searched 
from inception to March 2007 for literature on the 
effectiveness and cost-effectiveness of prophylaxis with 
palivizumab.
Review methods: The literature was systematically 
reviewed and current economic evaluations were 
analysed to identify which parameters were driving the 
different cost-effectiveness estimates. A probabilistic 
decision-analytical model was built to assess the cost-
effectiveness of prophylaxis with palivizumab for 
children at risk of RSV infection and the parameters 
populated with the best estimates thought most 
applicable to the UK. We also constructed a new model, 
the Birmingham Economic Evaluation (BrumEE). Cost-
effectiveness analyses were undertaken from both NHS 
and societal perspectives.
Results: Two randomised controlled trials (RCTs) 
were identified. Prophylaxis with palivizumab for 
preterm infants without chronic lung disease (CLD) or 
children with CLD resulted in a 55% reduction in RSV 
hospital admission: 4.8% (48/1002) in the palivizumab 
group and 10.6% (53/500) in the no prophylaxis 
group (p = 0.0004). Prophylaxis with palivizumab was 
associated with a 45% reduction in hospitalisation rate 
RSV among children with coronary heart disease (CHD). 
Hospitalisation rates for RSV were 5.3% (34/639) in 
the palivizumab group and 9.7% (63/648) in the no 
prophylaxis group (p = 0.003). Of existing economic 
evaluations, 3 systematic reviews and 18 primary studies 
were identified. All the systematic reviews concluded 
that the potential costs of palivizumab were far in excess 
of any potential savings achieved by decreasing hospital 
admission rates, and that the use of palivizumab was 
unlikely to be cost-effective in all children for whom it is 
recommended, but that its continued use for particularly 
high-risk children may be justified. The incremental 
cost-effectiveness ratios (ICERs) of the primary studies 
varied 17-fold for life-years gained (LYG), from £25,800/
LYG to £404,900/LYG, and several hundred-fold for 
quality-adjusted life years (QALYs), from £3200/QALY 
to £1,489,700/QALY for preterm infants without CLD 
or children with CLD. For children with CHD, the ICER 
varied from £5300/LYG to £7900/LYG and from £7500/
QALY to £68,700/QALY. An analysis of what led to the 
discrepant ICERs showed that the assumed mortality 
rate for RSV infection was the most important driver. 
The results of the BrumEE confirm that palivizumab 
does not reach conventional levels of cost-effectiveness 
in any of the licensed indications if used for all eligible 
children.
Conclusions: Prophylaxis with palivizumab is clinically 
effective for the reducing the risk of serious lower 
respiratory tract infection caused by RSV infection and 
requiring hospitalisation in high-risk children, but if 
used unselectively in the licensed population, the ICER 
is double that considered to represent good value for 
money in the UK. The BrumEE shows that prophylaxis 
with palivizumab may be cost-effective (based on a 
threshold of £30,000/QALY) for children with CLD 
when the children have two or more additional risk 
factors. Future research should initially focus on 
reviewing systematically the major uncertainties for 
patient subgroups with CLD and CHD and then on 
primary research to address the important uncertainties 
that remain.
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Glossary and list of abbreviations
Adverse effect An abnormal or harmful effect 
caused by and attributable to exposure to a 
chemical (e.g. a drug), which is indicated by 
some result such as death, a physical symptom 
or visible illness. An effect may be classed as 
adverse if it causes functional or anatomical 
damage, causes irreversible change in the 
homeostasis of the organism or increases the 
susceptibility of the organism to other chemical 
or biological stress.
Chronic lung disease Chronic lung disease 
is defined as oxygen dependency for at least 
28 days from birth. It is caused by prolonged 
supplemental oxygen therapy and ventilation 
and usually develops in the first 4 weeks 
after birth, most often affecting babies born 
prematurely. It is caused by the pressure and 
high concentrations of oxygen which, when 
prolonged, can cause lung tissue to become 
inflamed and scarred.
Confidence interval A measure of the 
precision of a statistical estimate; quantifies the 
uncertainty in measurement. Usually reported 
as 95% CI, i.e. the range of values within which 
one can be 95% sure that the true values for the 
whole population lie.
Discounting This refers to the process of 
adjusting the value of costs or benefits that 
occur at different points of time in the future 
so that they may all be compared as if they had 
occurred at the same time.
Incremental cost-effectiveness ratio An 
expression of the additional cost of health 
gain associated with an intervention relative 
to an appropriate comparator. Expressed as 
the difference in mean costs (relative to the 
comparator) divided by the difference in mean 
health gain.
Infant A child up to 1 year old (up to and 
including 365 days from birth).
Meta-analysis The statistical pooling of the 
results of a collection of related individual 
studies, to increase statistical power and 
synthesise their findings.
Quality of life A concept incorporating all the 
factors that might impact on an individual’s 
life, including factors such as the absence of 
disease or infirmity and also other factors that 
might affect their physical, mental and social 
well-being.
Quality-adjusted life-year (QALY) An index 
of health gain in which survival duration is 
weighted or adjusted by the patient’s quality 
of life during the survival period. QALYs have 
the advantage of incorporating changes in both 
quantity (mortality) and quality (morbidity) of 
life.
Odds A ratio of the number of people 
incurring an event to the number of people 
who do not have an event.
Odds ratio Ratio of odds of a specified 
characteristic in the treated group to the odds 
in the control group.
Risk ratio The ratio of risk in the treated 
group to the risk in the control group.
Glossary
Contents
viii
BrumEE Birmingham Economic Evaluation
BNF British National Formulary
BPD bronchopulmonary dysplasia
CBA cost–benefit analysis
CEA cost-effectiveness analysis
CEAC cost-effectiveness acceptability 
curve
CUA cost–utility analysis
CLD chronic lung disease
CHD congenital heart disease
CRD Centre for Review and 
Dissemination
CRIB clinical risk index for babies
DARE Database of Abstracts of Reviews of 
Effects
EED Economic Evaluation Database
ESRC Economic and Social Research 
Council
GA gestational age
HAP hospital admission prevented
HDS hospital day saved
HEED Health Economic Evaluation 
Database
HRQoL health-related quality of life
HUI Health Utility Index
ICER incremental cost-effectiveness ratio
ICU intensive care unit
IEA infection episode avoided
JCVI Joint Committee on Vaccination 
and Immunisation
MTRAC Midlands Therapeutic Review and 
Advisory Committee
NHS National Health Service
NIC net ingredient cost
NICU neonatal intensive care unit
LYG life-year gained
LRTI lower respiratory tract infection
ONS Office for National Statistics
OR odds ratio
PICU paediatric intensive care unit
PSA probabilistic sensitivity analysis
QALY quality-adjusted life-year
RCT randomised controlled trial
RDS respiratory distress syndrome
RNA ribonucleic acid
RSV respiratory syncytial virus
SAS siblings at school
SD standard deviation
UK United Kingdom
USA United States
List of abbreviations
All abbreviations that have been used in this report are listed here unless the abbreviation is well 
known (e.g. NHS), or it is has been used only once, or it is a non-standard abbreviation used only 
in figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in the 
notes at the end of the table.
Health Technology Assessment 2008; Vol. 12: No. 36
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
ix
Executive summary
Background
Respiratory syncytial virus (RSV) causes outbreaks 
of respiratory tract infection in the winter months 
in the UK. It is the leading cause of lower 
respiratory tract infection (LRTI) in infants and can 
lead to hospitalisation, particularly in those who 
are premature or who have chronic lung disease 
(CLD) or congenital heart disease (CHD). There 
are currently two licensed specific therapies in the 
UK: ribavirin and palivizumab. Palivizumab is a 
monoclonal antibody designed to provide passive 
immunity against RSV and thereby prevent or 
reduce the severity of RSV infection. It is licensed 
for the prevention of serious lower LRTI caused by 
RSV in children at high risk. While it is recognised 
that a policy of using palivizumab for all children 
who meet the licensed indication does not meet 
conventional UK standards of cost-effectiveness, 
most clinicians feel that its use is justified in 
some children. The purpose of this review is to 
determine if we can identify subgroups in whom 
palivizumab is cost-effective.
Objective
This review aims to systematically examine the 
scientific evidence about the effectiveness and cost-
effectiveness of palivizumab for the prevention of 
RSV in children and to look at prognostic factors 
to determine if it is possible to identify subgroups 
among which there are important differences in 
cost-effectiveness.
Methods
We systematically reviewed the literature about the 
effectiveness and cost-effectiveness of prophylaxis 
with palivizumab. Bibliographic databases were 
searched from inception to March 2007 with 
no date limits or language restrictions. Current 
economic evaluations were analysed to identify 
which parameters were driving the different 
cost-effectiveness estimates. A probabilistic 
decision-analytical model was built to assess the 
cost-effectiveness of prophylaxis with palivizumab 
for children at risk of RSV infection and the 
parameters populated with the best available 
estimate thought to be most applicable to the UK 
context. Data to inform parameters in our model 
were systematically sought from the identified 
trial data and pragmatically identified from 
observational studies in the wider literature. Meta-
analyses were carried out where appropriate.
Results
Clinical effectiveness
Two randomised controlled trials (RCTs) were 
identified. Prophylaxis with palivizumab for 
preterm infants without CLD or children with 
CLD resulted in a 55% reduction in RSV hospital 
admission: 4.8% (48/1002) in the palivizumab 
group and 10.6% (53/500) in the no prophylaxis 
group (p = 0.0004).
Prophylaxis with palivizumab was associated 
with a 45% reduction in RSV hospitalisation rate 
among children with CHD. Hospitalisation rates 
for RSV were 5.3% (34/639) in the palivizumab 
group and 9.7% (63/648) in the no prophylaxis 
group (p = 0.003). A slightly higher mortality in 
the control group was found in both RCTs, but this 
was not statistically significant. However, the trials 
were not powered to demonstrate a difference. 
Palivizumab had a relatively safe adverse event 
profile.
Cost-effectiveness
Existing economic evaluations
Three systematic reviews and 18 primary studies 
were identified. All the systematic reviews stated 
that the potential costs of palivizumab were far in 
excess of any likely savings achieved by decreasing 
hospital admission rates, and that the use of 
palivizumab was unlikely to be cost-effective in all 
children for whom it is recommended, but that 
continued use of palivizumab for particularly high-
risk children may be justified. The incremental 
cost-effectiveness ratios (ICERs) of the primary 
studies varied 17-fold for life-years gained (LYG), 
from £25,800/LYG to £404,900/LYG, and several 
hundred-fold for quality-adjusted life-years 
(QALYs), from £3200/QALY to £1,489,700/QALY 
for preterm infants without CLD or children with 
CLD. For children with CHD, the ICER varied 
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from £5300/LYG to £7900/LYG and from £7500/
QALY to £68,700/QALY.
An analysis of what led to the discrepant ICERs 
showed that the assumed mortality rate for RSV 
infection was the most important driver. The 
rates of hospital and paediatric intensive care unit 
(PICU) admissions and sequelae of RSV also had 
measurable effects.
Birmingham Economic 
Evaluation (BrumEE)
We undertook an independent economic 
evaluation. The resource use and unit cost were 
obtained from the trial studies, British National 
Formulary (BNF), Office for National Statistics 
(ONS), Economic and Social Research Council 
(ESRC) and previous economic evaluation studies. 
The utilities were obtained from a UK cohort study. 
Cost-effectiveness analyses were undertaken from 
both NHS and societal perspectives. Estimates 
from an NHS perspective derived using different 
methods confirm that palivizumab does not reach 
conventional levels of cost-effectiveness in any 
of the licensed indications if used for all eligible 
children – the lowest ICER being £64,000/QALY.
When additional risk factors for RSV 
hospitalisation derived from observational studies 
(gestational age, age at the start of the RSV season, 
having siblings who are in day care or at school) 
were modelled using the BrumEE, prophylaxis 
against RSV infection with palivizumab was within 
the willingness-to-pay threshold of £30,000/QALY 
in a number of important subgroups of children 
with CLD. There was insufficient data to undertake 
a similar risk group analysis for children with CHD.
Conclusion
Prophylaxis with palivizumab is clinically effective 
for reducing the risk of serious LRTI caused by 
RSV infection and requiring hospitalisation in 
high-risk children, but if used unselectively in the 
licensed population the ICER is over £60,000/
QALY, which is double that considered to represent 
good value for money in the UK (the current 
willingness-to-pay threshold is about £30,000/
QALY). The BrumEE shows that prophylaxis with 
palivizumab may be cost-effective (based on a 
threshold of £30,000/QALY, but the threshold for 
decision-makers may vary, particularly for this type 
of patient group) for children with CLD when the 
children have two or more additional risk factors.
Our economic evaluation is limited by the quality 
and quantity of the primary data available and the 
pragmatic rather than systematic methods used to 
identify parameter values. Future research should 
initially focus on reviewing systematically the major 
uncertainties for patient subgroups with CLD and 
CHD (e.g. mortality rates for RSV infection in 
children not given palivizumab prophylaxis) and 
then on primary research to address the important 
uncertainties that remain.
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Chapter 1  
Introduction
Aim of this health 
technology assessment
This assessment aims
to review systematically the scientific evidence •	
on the effectiveness and cost-effectiveness of 
palivizumab for the prevention of respiratory 
syncytial virus (RSV) infection in children
to model the cost-effectiveness of palivizumab •	
for prevention of RSV infection in children
to look at prognostic factors for RSV infection •	
with at view to the identification of subgroups 
of children for whom there may be important 
differences in cost-effectiveness.
Background
Description of underlying 
health problem
RSV causes outbreaks of respiratory tract infection 
in the UK, especially in the winter months. It can 
affect people of any age and is usually a mild, 
self-limiting illness. It is most serious in infants 
and young children, in whom it is the single 
most important cause of lower respiratory tract 
infection (LRTI). RSV infection can present with 
a wide range of severity from mild respiratory 
symptoms, to rhinitis and otitis media, through to 
bronchiolitis, tracheobronchiolitis and pneumonia 
with significant morbidity and a very small 
increased risk of death.
RSV is an RNA virus that is highly communicable. 
Humans are the only known reservoir. The virus 
is spread by contaminated nasal secretions via 
respiratory droplets, so close contact with an 
infected individual or contaminated surface 
is required for transmission. RSV can persist 
for several hours on toys or other objects. Risk 
factors for RSV infection include crowding, low 
socioeconomic status, exposure to tobacco smoke 
and admission to hospital during the RSV season 
(late autumn to early spring).
Immunity to RSV following infection is not 
complete or enduring, and recurrent infection is 
frequent. In children followed up from birth in 
the Houston Family Study, the infection rate was 
68.8% in children aged less than 12 months, of 
whom 82.6% were reinfected in their second year 
and 46% were reinfected during their third year.1 
The fact that older children and adults are usually 
protected against RSV-related LRTIs suggests that 
primary infections may protect against later severe 
disease. Approximately 50% of infants and young 
children become infected each year. In a study 
from the USA, about 0.5–2% of children infected 
with RSV required hospital admission.2 All but one 
child had been infected at least once by 24 months 
of age, and about one half had experienced two 
infections. LRTI was common (22.4% during year 1 
and 13.0% during year 2). Most children had only 
one LRTI.1 The risk of reinfection was inversely 
related to the level of neutralising antibodies in the 
serum. Reinfection illnesses tended to be mild and 
risk of reinfection decreased to 33.3% during year 
4.1 Other studies suggest that 40% of primary RSV 
infections lead to clinical bronchiolitis.3
Those most at risk from severe disease if infected 
with RSV are infants under 6 weeks old or who 
have chronic lung disease (CLD), congenital heart 
disease (CHD) or immunodeficiency, and those 
born prematurely (at 35 weeks gestational age or 
before).
The definition of chronic lung disease accepted by 
the Department of Health’s Joint Committee on 
Vaccination and Immunisation (JCVI) is oxygen 
dependency for at least 28 days from birth.4 CLD is 
caused by prolonged supplemental oxygen therapy 
and ventilation. It usually develops in the first 4 
weeks after birth and most often affects babies born 
prematurely. It is caused by the pressure and high 
concentrations of oxygen which, when prolonged, 
can cause lung tissue to become inflamed and 
scarred. Since the lungs do not work properly, 
babies with CLD may have trouble breathing 
and are at increased risk of LRTI. Moreover, as 
they develop problems more quickly than other 
children, when pulmonary infection does occur, 
they are more likely to be admitted to hospital.
As a child grows and gets older, the area of 
tissue damage becomes less important and their 
condition improves. Children with CLD are 
therefore most vulnerable during their first 2 years 
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of life. This condition was previously known as 
bronchopulmonary dysplasia (BPD).
Children from high-risk groups constitute 53% of 
all children hospitalised with RSV. Mortality is less 
than 1% in children without underlying illness. 
Mortality in those with heart and lung disease who 
are hospitalised is estimated to be around 3–5%.5
Although many potential vaccines have been 
tested or are under development, there is currently 
no vaccine available. One of the challenges to 
developing a vaccine is the fact that the host 
immune responses play a role in the pathogenesis 
of the disease: early studies showed that children 
vaccinated with a formalin-inactivated RSV vaccine 
suffered from more severe disease on subsequent 
exposure to the virus than did unvaccinated 
control subjects and the trials resulted in the 
hospitalisation of 80% of vaccinees and two deaths.6
There are currently only two licensed specific 
therapies in the UK: ribavirin, which is licensed for 
the treatment of severe bronchiolitis caused by RSV, 
and palivizumab.
Description of new intervention
Palivizumab (Synagis®) is an antibody designed 
to provide passive immunity against RSV by 
preventing RSV entry in host cells and thereby 
preventing or reducing the severity of RSV 
infection. It is a humanised murine monoclonal 
antibody produced by recombinant technology and 
directed against the surface RSV fusion protein. 
This protein is essential for RSV to enter the host 
target cell.
Palivizumab was first licensed in the USA in June 
1998 and across Europe in 1999 with a licensing 
extension in November 2003. It is currently 
licensed for the prevention of serious RSV-related 
LRTI requiring hospitalisation in children who are:
born at •	 ≤ 35 weeks’ gestation and are less than 
6 months of age at the start of the RSV season
< 2 years of age and have required treatment •	
for BPD within the last 6 months
< 2 years of age and have haemodynamically •	
significant congenital heart disease.
Current usage in the NHS
It is difficult to obtain accurate data about current 
practice in the UK. We first outline below some of 
the important UK guidance that is available and 
then give data on prescribing practice.
UK guidance on use 
of palivizumab
The British National Formulary for Children (BNFC) 
acknowledges that ‘many areas of paediatric 
practice have suffered from inadequate information 
on effective medicines’ and provides guidance 
based on information validated against emerging 
evidence, best practice guidelines and advice 
from clinical experts. Its advice on prescribing, 
therefore, may go beyond the licensed paediatric 
indications. In the case of palivizumab, the BNFc 
indicates that local guidelines should be consulted 
and states that palivizumab should be prescribed 
under specialist supervision and on the basis of the 
likelihood of hospitalisation and that the first dose 
should be administered before the RSV season.7 
Hence, clinicians are recommended to take a risk-
based approach in line with local guidelines.
Examples of local guidance from the West 
Midlands Region (where the authors are based) are 
given below. The Midlands Therapeutic Review 
& Advisory Committee (MTRAC), which makes 
recommendations about the appropriate use of 
drugs in primary care, recommended in 2000:
Restricted Use: The decision to use 
palivizumab should be made by a specialist. It 
is then appropriate for general practitioners 
to prescribe and administer the course of 
intramuscular injections.8
This advice is still current. The recommendation 
of the West Midlands Regional Advisory Panel 
(which advises healthcare commissioners about the 
appropriate use of technologies) in 2001 was:
Borderline: It is reasonable to assume that 
if hospital admission can be prevented then 
mortality may fall also. However, although the 
trial results were consistent with such a fall, the 
trial was not large enough to demonstrate a 
statistically significant reduction in death rates 
in high risk infants. The panel do not see any 
reason to change the current usage in high risk 
cases at tertiary centres.9
The Scottish Intercollegiate Guidelines Network 
has produced a guideline on bronchiolitis that 
concludes that palivizumab is effective but not 
cost-effective (based on the UK ICER threshold of 
£30,000/QALY). It therefore recommends that it 
should not be used routinely. It may, however, be 
used on a case-by-case basis in infants under 12 
months of age with extreme prematurity, acyanotic 
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congenital heart disease, congenital or acquired 
significant lung diseases or immune deficiency. A 
local lead specialist should work with clinical teams 
to identify who might benefit from palivizumab.10
A working group of the British Paediatric 
Cardiac Association has developed expert group 
recommendations intended to assist clinicians 
in prescribing palivizumab to young children 
with CHD. They suggest that prophylaxis should 
be offered to infants with haemodynamically 
significant lesions, particularly increased 
pulmonary blood flow with or without cyanosis, 
pulmonary venous congestion, pulmonary 
hypertension or long-term pulmonary 
complications, residual haemodynamic 
abnormalities following medical or surgical 
intervention or cardiomyopathy requiring 
treatment, and to children likely to need admission 
for cardiac interventions in the RSV season. 
Prophylaxis at the clinician’s discretion might 
be indicated in children with complex cardiac 
conditions aged over 1 year.11 This is a different 
risk stratification to that used in the RCT of 
palivizumab in children with CHD.12
The Joint Committee on Vaccination and 
Immunisation (UK) recommends the use of 
palivizumab for children under 2 years with CLD 
on home oxygen or with prolonged use of oxygen; 
infants under 6 months old with left-to-right shunt, 
haemodynamically significant CHD, or pulmonary 
hypertension; and children under 2 years with 
severe congenital immunodeficiency.13 It should 
be noted that the last recommendation is based on 
clinical judgement rather than research evidence 
and is outside the licensed indication.
It can be seen that the guidance available to 
clinicians recommends prescribing to children who 
are at particularly high risk but not to all children 
meeting the indication. The guidance is based 
more on the poor cost-effectiveness of palivizumab 
prophylaxis when given to all those eligible for 
treatment under the licensed indication than on 
high-quality evidence of increased effectiveness 
within the suggested risk groups.
Prescribing of palivizumab
We were unable to identify an audit or obtain up-
to-date data on prescribing of palivizumab across 
the UK for secondary or tertiary care. However, 
worldwide, palivizumab is increasingly used, and 
sales generated a revenue of about US$1.2 billion 
in 2005.14 In England and Wales there is no specific 
funding for palivizumab.
Anecdotally, secondary care clinicians we spoke 
to told us they would like to use this drug more 
because it is effective but they actually do so rarely 
because the very high opportunity cost would 
have a detrimental effect on their prescribing 
budgets. Such anecdotal reports, however, may 
reflect a biased view of clinical opinion. Therefore, 
we sought data on prescribing in primary and 
secondary care. Data for both the West Midlands 
and for England were provided to us by colleagues 
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at the Department of Medicines Management at 
Keele University and are presented graphically in 
Figures 1 and 2. Primary care prescribing shows a 
predictable seasonal pattern and highly restricted 
use. The net ingredient cost (NIC) of palivizumab 
prescribed in primary care in England was £39,000 
in 2005 and £44,000 in the first 10 months of 
2006.14 The figure suggests that the West Midlands 
has high levels of primary care prescribing, but 
without national data on secondary care prescribing 
it is impossible to tell whether the region has high 
overall palivizumab prescribing.
Figure 3 shows secondary care prescribing by item 
in the West Midlands (excluding FP10 prescriptions 
written by hospital prescribers but dispensed in 
the community) provided by the Department of 
Medicines Management, Keele University. It can be 
seen that most prescribing originates in secondary 
care and there was an approximate doubling of 
palivizumab prescribing in 2007 over 2006.
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Methods for reviewing 
effectiveness
Search strategy
The following sources were searched:
bibliographic databases: Cochrane Library •	
(Wiley internet version) 2007 Issue 1, 
MEDLINE (Ovid) 1950 to March Week 2 2007, 
MEDLINE In-Process (Ovid) at March 26, 
2007, EMBASE (Ovid) 1980 to 2007 Week 12, 
CINAHL (Ovid) 1982 to March 2007, Science 
Citation Index (Web of Knowledge) at 26 
March 2007
research registries of ongoing trials including •	
National Research Register, Current Controlled 
Trials metaRegister and Clinical Trials.gov
reference lists of relevant studies•	
relevant internet sources•	
No date limits or language restrictions were 
applied. Details of search strategies are given in 
Appendix 1, Search strategies – effectiveness.
Inclusion and exclusion criteria
Studies were included if they were RCTs or 
systematic reviews of RCTs that:
included at least some high-risk children•	
used palivizumab in a preventative setting •	
at a dose and frequency comparable to that 
described in the licence.
Where a mixed population of high-risk and 
non-high risk children was reported, data were 
extracted for the relevant subgroups where 
possible. High-quality observational studies 
were also retrieved for consideration of adverse 
events, prognostic factors and other parameters 
required for the decision-analytical model where 
these were not obtainable from RCTs. Titles and 
were examined for inclusion by two reviewers 
independently. Disagreement was resolved by 
consensus.
Studies were excluded if they were:
non-randomised studies•	
trials conducted exclusively in non-high-risk •	
children
trials using a single dose of palivizumab or a •	
dose that is not comparable to that currently 
used in clinical practice
animal models•	
preclinical and biological studies or•	
narrative reviews, editorials, opinions.•	
Reports published as meeting abstracts only 
were also excluded if there were insufficient 
methodological details to allow the study quality to 
be appraised.
Data extraction strategy
Data were extracted independently by one reviewer 
using a standardised data extraction form and 
checked by a second reviewer. Discrepancies were 
resolved by discussion.
Quality assessment strategy
The quality of included studies has been assessed 
according to guidelines proposed in NHS CRD 
(Centre for Review and Dissemination) Report No. 
415 by one reviewer, and independently checked for 
agreement by a second reviewer. Disagreements 
were resolved by discussion.
Results for clinical 
effectiveness
Search results for 
clinical effectiveness
The searches for studies of effectiveness identified 
601 citations, and 17 papers were retrieved after 
elimination of duplicate citations and exclusions 
made on scanning the title and abstract (Figure 4). 
Of these 17 papers, 14 were excluded on reading 
the paper. Excluded studies included early-phase 
palivizumab studies with intravenous, rather than 
intramuscular, administration and two open-label 
safety studies (these included adverse event data; 
Appendix 5, Table 43).
Two RCTs of palivizumab (IMpact16 and Feltes12) 
and one systematic review17 that met the 
Chapter 2  
Clinical effectiveness
Clinical effectiveness
6
601 citations retrieved
554 remaining after removal of duplicates
17 retrieved
+
14 excluded after reading paper
2 randomised
controlled trials
537 excluded after
inspection of abstract,
title and bibliographic
references
5 reviews in total
(1 systematic review
identified in effectiveness
searches + 4 additional
reviews identified in health
economics searches
FIGURE 4 Flow chart showing identification of effectiveness studies.
inclusion criteria were identified from the clinical 
effectiveness searches. Additional systematic 
reviews were identified in the economic searches 
(see Table 1 for details) and were read to see if 
they contained additional useful information on 
effectiveness. None of these systematic reviews, 
however, included any trials other than those 
identified in the searches or included formal meta-
analyses.
Summary of included RCTs
Data on study quality, design and results was 
abstracted from the two included RCTs. Both 
TABLE 1 Systematic reviews
Study Comments
Raya et al., 200618 Update. Systematic review as part of cost-effectiveness study. Population: preterm 
babies. One trial and one cohort study included
Dunfield and Mierzwinski-Urban, 
200717
Postdates effectiveness searches. Includes IMpact and Feltes
Viswanathan et al., 200319 Cited in Dunfield and Mierzwinski-Urban, 200717
Embleton et al., 200520 Cited in Dunfield and Mierzwinski-Urban, 2007,17 Population: preterm children. 
Included IMpact, Subramanian, 1998,21 and Saez-Llorens, 199822
Simpson and Burls, 20019a Health technology assessment
a Identified in the health economics searches.
studies were of high quality. They were randomised 
with adequate concealment of allocation, double-
blind and with loss to follow-up clearly reported 
and high level of follow-up of trial patients.
Trial populations
The patient population of one trial (IMpact) was 
premature infants aged ≤ 6 months or children 
aged ≤ 2 years with bronchopulmonary dysplasia 
(BPD) that had required treatment in the last six 
months. The population of the other trial was 
children aged ≤ 2 years with haemodynamically 
or partially corrected congenital heart disease 
(Table 2).
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TABLE 2 Characteristics of the randomised control trials 
Study Population Inclusion/exclusion criteria Intervention Comparator
IMpact-
RSV Study 
Group 
199816
≤ 35 weeks’ 
gestation and 
aged 6 months 
or younger or 
24 months old 
or younger with 
clinical diagnosis 
of BPD requiring 
ongoing medical 
treatment in last 6 
months
Exclusion: hospitalisation anticipated to last > 30 days or 
mechanic ventilation at time of entry; life expectancy < 6 
months; active or recent RSV infection; hepatic or renal 
dysfunction or seizure disorder or immunodeficiency or 
allergy to IgG products; receipt of RSV immunoglobulin 
within 3 months; previous receipt of RSV vaccines, 
palivizumab, other monoclonal antibodies or other 
investigational agents; congenital heart disease except 
patient ductus arteriosus or uncomplicated and 
haemodynamically insignificant septal defect
Palivizumab 
15 mg/kg 
i.m. every 30 
days for five 
doses; 2:1 
randomisation
Placebo
Feltes et 
al., 200312
≤ 24 months old, 
haemodynamically 
significant CHD 
and unoperated or 
partially corrected 
CHD
Exclusion: cardiac respiratory instability; survival not 
expected; cardiac transplant planned/anticipated; 
hospitalised (unless discharge anticipated within 21 
days); anticipated cardiac surgery within 2 weeks 
of randomisation; mechanical cardiac or respiratory 
support; anomalies/end-organ dysfunction so anticipate 
survival < 6 months; unstable; HIV/RSV/other acute 
infection/illness; investigational agents within the 
previous 3 months; uncomplicated small atrial or 
ventricular septal defects or patient ductus arteriosus
Palivizumab 
15 mg/kg i.m. 
every 30 days 
for five doses
Placebo
CHD, congenital heart disease; HIV, human immunodeficiency virus; IgG, immunoglobulin G; i.m., intramuscularly; RSV, 
respiratory syncytial virus.
TABLE 3 Study characteristics: outcomes and follow-up
Study Primary outcome Secondary outcomes
Length of 
follow-up
IMpact-RSV 
Study Group, 
199816
(1) Hospitalisation for respiratory illness and 
positive RSV antigen in respiratory secretions 
or (2) hospitalised for other reasons and 
positive RSV test and LRI score ≥ 3 and at 
least one point higher than last pre-illness 
visit
Days hospitalised; RSV hospitalisation days 
with increased supplemental oxygen; total 
days moderate/severe respiratory infection 
(LRI score); frequency and total days in 
ICU and mechanical ventilation; clinically 
diagnosed otitis media; adverse events
150 days
Feltes et al., 
200312
Incidence of RSV hospitalisation including 
primary (acute cardiorespiratory illness, 
RSV antigen positive within 48 h before/after 
admission) and nosocomial hospitalisations; 
deaths outside hospital demonstrated to be 
associated with RSV
Total days hospitalised; days on supplemental 
oxygen; days in ICU; days on mechanical 
ventilation; adverse events
150 days
ICU, intensive care unit; LRI, lower respiratory illness/infection; RSV, respiratory syncytial virus.
Intervention and comparator
Both trials compared palivizumab 15 mg/kg i.m. 
every 30 days for five doses with placebo.
Outcome measures
The primary outcome in both studies was 
hospitalisation with proven RSV infection. 
Secondary outcomes are listed in Table 3.
Summary of studies
The design and baseline characteristics of the two 
RCTs are described in Tables 2, 3 and 4.
IMpact-RSV
The IMpact-RSV16 trial was conducted in 1998 for 
infants born at ≤ 35 weeks of gestation or children 
with CLD using the now outdated clinical term 
and definition BPD. However, it is likely that the 
BPD patient population is very similar to the CLD 
population. A total of 1502 children who were born 
at ≤ 35 weeks gestational age and who were ≤ 6 
months old at the beginning of RSV season, or who 
were diagnosed with CLD and were ≤2 years old at 
the beginning of RSV season, were included in the 
study.
Clinical effectiveness
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TABLE 4 Results: recruitment and baseline
Study
n, 
intervention
n, 
control
Baseline 
characteristics Dosing Follow-up
IMpact-RSV 
Study Group, 
199816
1002 500 Balanced except number 
of smokers in household: 
69% palivizumab, 63% 
control
Five injections: 92% 
palivizumab and 94% 
placebo
1486 completed follow-
up: 99% palivizumab, 
99% placebo
Feltes et al., 
200312
639 648 Balanced Five injections: 93.0% 
palivizumab and 91.8% 
placebo
95.6% of palivizumab and 
95.5% of placebo group 
completed the study
The children were randomised to receive 15 mg/
kg palivizumab (1002 infants) or placebo (500 
infants) every 30 days during the RSV season. 
A total of five doses were administered over 4 
months. The infants were followed up for 150 days 
from randomisation in order to cover the first RSV 
season the babies were exposed to. The primary 
end point was hospital admission for respiratory 
illness and a positive test for RSV or, in the case of 
children who were already hospitalised, a positive 
RSV test with a moderate lower respiratory tract 
illness score of 3.16 (Lower respiratory illness 
score: 0 = no respiratory illness, 1 = upper 
respiratory tract illness, 2 = mild lower respiratory 
tract illness, 3 = moderate lower respiratory 
tract illness, 4 = severe lower respiratory tract 
illness, 5 = mechanical ventilation.) Prophylaxis 
with palivizumab resulted in a 55% reduction in 
RSV hospital admission, with 4.8% (Table 5) in 
palivizumab group and 10.6% (Table 5) in the no 
prophylaxis group (p = 0.0004). The study also 
reported RSV hospital admissions for subgroups 
of children. For preterm infants without CLD, 
the reduction in RSV hospital admission was 78% 
(Table 5) (p = 0.001). For children with CLD, the 
reduction in RSV hospital admission was 39% (Table 
5) (p = 0.038). The reported subgroup analysis 
does not in itself demonstrate a difference in effect 
sizes for the two groups. Using the values reported, 
a test for interaction is marginally significant 
(p = 0.05), suggesting that palivizumab may be 
more effective in reducing hospitalisations for 
premature children than for those with CLD.
The number of children reporting adverse events 
judged by the blinded investigator to be related 
to the treatment was similar in the placebo and 
palivizumab groups. The reported adverse events 
included injection site reactions, fever and rash. 
These events were generally mild and of short 
duration. None was serious. Four deaths (0.4%) 
were reported in the palivizumab group and 
five deaths (1%) were reported in the placebo 
group. No deaths were judged to be related to 
palivizumab. Two studies23,24 reported the mortality 
rates for those who were admitted to hospital due 
to RSV infection. Meta-analysis of these studies 
gives a mortality rate of 6.68% for RSV hospital 
admission. However, this mortality rate might not 
be RSV related. The study by Nuijten et al.25 used 
a mortality rate of 8.11% for RSV hospitalisation 
group (taken from the Sampalis and Sampalis23 
study, which is discussed below), which is the main 
reason that the study reported a lower ICER.
Feltes et al.
The RCT by Feltes et al.12 was conducted for 
children with CHD. A total of 1287 children aged 
≤ 24 months were randomised to receive 15 mg/
kg palivizumab (639 children) or placebo (648 
children) every 30 days during the RSV season. 
The children were followed up for 150 days from 
randomisation to cover exposure to the relevant 
RSV season. The results showed that monthly 
prophylaxis with palivizumab was associated with 
a 45% reduction in RSV hospitalisation rate. RSV 
hospitalisation rates were 5.3% (Table 5) in the 
palivizumab group and 9.7% (Table 5) in the no 
prophylaxis group. The reduction was statistically 
significant with a p-value of 0.003. The RCT 
reported RSV hospitalisation rates of 5.6% (Table 
5) for prophylaxis with palivizumab and 7.9% 
(Table 5) for no prophylaxis in the cyanotic stratum 
(pulmonary atresia with ventricular /intact septum, 
tetralogy of Fallot, single ventricle including 
hypoplastic right/left heart, tricuspid atresia, 
double-outlet right ventricle with transposed 
arteries, Ebstein anomaly, D-transposition of great 
arteries) with a p-value of > 0.05, and 5% vs 11.8% 
in the acyanotic stratum with a p-value of 0.003. 
These correspond to a 29% reduction in RSV 
hospitalisation for children with cyanotic CHD, and 
a 58% reduction in RSV hospitalisation for children 
with acyanotic CHD. A test for interaction suggests 
that there is no evidence of a difference in effects 
between cyanotic and acyanotic CHD (p > 0.1). 
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The external validity of this study is questionable 
– a cohort study in Switzerland by Duppenthaler 
et al.26 reported that RSV hospitalisation rates in 
CHD patients less than 24 months of age varied 
from 0.5% to 2.5%, rates that are much lower 
than that reported by Feltes et al.12, suggesting 
that the RCT may have recruited patients with 
particularly serious conditions. Switzerland is the 
same continent as the UK and is at similar latitude. 
Hence, RSV seasons are likely to be comparable.
The reported adverse events included injection 
site reactions, fever, conjunctivitis, arrhythmia and 
cyanosis. The numbers of adverse events reported 
were similar in the palivizumab group and the no 
prophylaxis group. Twenty-one deaths (3.3%) were 
reported in the palivizumab group and 27 deaths 
(4.2%) were reported in the placebo group. No 
deaths were attributed to palivizumab.
Recruitment and baseline characteristics of the two 
studies are reported in Table 4. The IMpact study 
had a 2:1 palivizumab–placebo randomisation, 
whereas the CHD trial had a 1:1 randomisation. 
There were few differences in the distribution of 
baseline characteristics between trial arms. As the 
baseline characteristics were balanced, confounding 
factors were unlikely to have influenced the 
outcomes of palivizumab.
As the populations of the two trials were different, 
premature infants and children with BPD and 
children with congenital heart disease, quantitative 
synthesis was not attempted.
In both trials, around 10% of patients in the 
placebo arm were hospitalised with RSV infection. 
There was a significant reduction in the risk of 
hospitalisation with palivizumab, 55% (95% CI 
38–72%) in premature infants and children with 
CLD and 45% (95% CI 23–67%) in children with 
CHD (Table 5).
Secondary outcome results are reported in Table 
6. Both trials reported a reduction in the days 
hospitalised. The risk of ICU admission and ICU 
days were significantly reduced in premature 
infants and children with CLD, but not in children 
with CHD. In the IMpact study, days hospitalised 
and days hospitalised for respiratory infections 
were reduced, but days of mechanical ventilation 
and non-respiratory hospitalisation and the 
incidence of otitis media were not reduced. In 
the Feltes et al.12 study, days with supplemental 
oxygen in the course of an RSV admission were 
significantly reduced, but ICU admissions, ICU 
days, mechanical ventilation and mechanical 
ventilation days were not significantly reduced.
TABLE 5 Results: primary outcomes
Study
Primary outcome result: 
intervention
Primary outcome result: 
control
Primary outcome result: 
intervention vs control
IMpact-RSV 
Study Group, 
199816
RSV hospitalisation: 48/1002 
4.8%:
RSV hospitalisation: 53/500 
(10.6%)
Reduction in RSV hospitalisation 
with palivizumab 55% (95% CI 
38–72%) (p = 0.0004) 
With CLD: 39/496 (7.9%) With CLD: 34/266 (12.8%) With CLD: 39% (95% CI 20–
58) (p = 0.038)
Premature no CLD: 9/506 
(1.8%)
Premature no CLD: 19/234 (8.1%) Premature no CLD 78% (95% 
CI 66–90) (p < 0.001)
Feltes et al., 
200312
RSV hospitalisation: 34/639 
(5.3%)
RSV hospitalisation: 63/648 (9.7%) Reduction in RSV hospitalisation 
with palivizumab: 45% (95% CI 
23–67) (p = 0.003 )
Cyanotic (pulmonary atresia with 
ventricular septum defect/intact 
septum, tetralogy of Fallot, single 
ventricle including hypoplastic 
right/left heart, tricuspid atresia, 
double-outlet right ventricle 
with transposed arteries, Ebstein 
anomaly, D-transposition of great 
arteries): n = 339 (5.6%)
Cyanotic (pulmonary atresia with 
ventricular septum defect/intact 
septum, tetralogy of Fallot, single 
ventricle including hypoplastic 
right/left heart, tricuspid atresia, 
double-outlet right ventricle 
with transposed arteries, Ebstein 
anomaly, D-transposition of great 
arteries): n = 343 (7.9%)
29% (p = 0.285)
Non-cyanotic: n = 300 (5.0%) Non-cyanotic: n = 305 (11.0%) 58% (p = 0.003)
CLD, chronic lung disease; RSV, respiratory syncytial virus.
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Subgroups
In the IMpact trial, pre-specified subgroups were 
premature infants and children with CLD. There 
was a reduction in the risk of RSV hospitalisation 
in both groups, with a greater reduction in the 
premature (78%; 95% CI 66–90%) than in the CLD 
group (39%; 95% CI 20–58%) (Table 5). This is a 
marginally significant difference in effect between 
the two groups (p = 0.05).
In the trial by Feltes et al.12, pre-specified subgroups 
were cyanotic and non-cyanotic heart disease 
(see Table 5 for precise definition), with a non-
significant 29% reduction in RSV hospitalisation in 
TABLE 6 Results: secondary outcomes 
Study
Secondary outcomes results: 
intervention Secondary outcomes results: control
Secondary outcomes 
results: intervention 
vs control
IMpact-RSV 
Study Group, 
199816
Days per 100 children Days per 100 children
 Hospitalised: 36.4  Hospitalised: 62.6 p < 0.001
 Increased oxygen: 30.3  Increased oxygen: 50.6 p < 0.001
 LRI ≥ 3: 29.6  LRI score ≥ 3: 47.4 p < 0.001
ICU admission: 1.3% ICU admission: 3% p = 0.026
Total ICU days:13.3 Total ICU days: 12.7 p = 0.023
Mechanical ventilation: 0.7% Mechanical ventilation: 0.2% p = 0.280
Total mechanical ventilation days: 8.4 Total mechanical ventilation days: 1.7 p = 0.210
Hospitalisation Hospitalisation
 Total 24%  Total 31% p = 0.011
 Respiratory: 16%  Respiratory: 22% p = 0.008
 Unrelated to RSV: 13%  Unrelated to RSV: 14% p = 0.470
Hospitalisation days per 100 children Hospitalisation days per 100 children:
 Total: 191  Total: 242 p = 0.005
 Respiratory: 124  Respiratory: 180 p = 0.004
 Unrelated to RSV: 88  Unrelated to RSV: 118 p = 0.369
Otitis media: 42% Otitis media: 40% p = 0.505
Feltes et al. 
200312
Relative reduction: % 
(p-value)
Days RSV hospitalisation Days RSV hospitalisation
 Total days: 367  Total days: 836
 Total days/100 children: 57.4  Total days/100 children: 129.0 56% (p = 0.003)
RSV hospital days of increased 
supplemental oxygen therapy
RSV hospital days of increased 
supplemental oxygen therapy
 Total days: 178  Total days: 658
 Total days/100 children: 27.9  Total days/100 children: 101.5 73% (p = 0.014)
 ICU admission: 13 (2%) ICU admission: 24 (3.7%) 46% (p = 0.094)
Days of ICU stay Days of ICU stay
 Total: 101  Total: 461
 Total days/100 children 15.9  Total days/100 children: 71.2 78% (p = 0.080)
Mechanical ventilation: 8 (1.3%) Mechanical ventilation: 14 (2.2%) 41% (p = 0.282)
Days of mechanical ventilation Days of mechanical ventilation
 Total days: 42  Total days: 354
 Total days/100 children: 6.5  Total days/100 children: 54.7 88% (p = 0.224)
ICU, intensive care unit; RSV, respiratory syncytial virus.
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the cyanotic group and a 58% reduction in the non-
cyanotic group (p = 0.003). A test for interaction 
suggested no evidence of a difference in effect 
between the two groups.
Overall adverse events
Adverse effects are given in Table 7. There was 
no evidence that palivizumab was associated 
with greater frequency of adverse events or 
associated with serious adverse events. The most 
frequently reported events believed to be related 
to palivizumab were injection site reactions, fever 
and nervousness. Events were generally mild and 
of short duration. Antibodies to palivizumab were 
detected in about 1% of infants in the IMpact study. 
There were no differences in death rates but the 
trials were not statistically powered to show such a 
difference.
A small study of 88 infants from IMpact evaluated 
the safety of palivizumab for a second season.27 Of 
the 88 infants studied, 56 received palivizumab 
for a second season. Mean age at entry to this 
study was 16 months, and approximately 20% of 
infants had CLD. Palivizumab was administered 
at the same dose and frequency as before. The 
researchers reported no local or systemic reactions 
suggestive of a possible immune-mediated 
response.
Summary of 
effectiveness results
There is limited good-quality evidence from 
two trials that palivizumab reduces the need for 
hospitalisation due to RSV by around 50% in the 
trial populations and is relatively safe.
Subgroup analysis suggested that palivizumab 
may be more effective in premature babies than in 
children with CLD. It could be speculated that this 
may be related to a greater need for hospitalisation 
with milder infection in the CLD group.
The reduction in RSV hospitalisation was also 
slightly greater in children with non-cyanotic rather 
than cyanotic congenital heart disease (see Table 
5), but this trial was underpowered to detect a 
difference between these subgroups and there is no 
evidence of a true underlying difference in effect 
size.
Although we outlined in the protocol that other 
high-risk groups, for example children with cystic 
fibrosis or immune deficiency, would be assessed, 
we have not found the relevant data for cystic 
fibrosis or immune deficiency subgroups.
TABLE 7 Results: adverse events
Study Adverse event Intervention Comparator
IMpact-RSV 
Study Group, 
199816
Children reporting adverse events 11% 10%
Deaths (not considered related to intervention) 4 (0.4%, two during 
RSV admission)
5 (1.0%)
Fever 2.8% 3.0%
Nervousness 2.5% 2.6%
Injection site reaction 2.3% 1.6%
No statistically significant differences in prevalence of other 
adverse events (prevalence ≤ 1%)
Feltes et al., 
200312
Children reporting adverse events 611 (95.6%) 625 (96.5%)
Deaths (p = 0.463) 21 (3.1%) 27 (4.2%) 
Cardiovascular (p = 0.180) 286 (44.8%) 315 (48.6%)
Respiratory (p = 0.296) 525 (82.2%) 547 (84.4%)
Requiring medical intervention (p = 0.392) 588 (92.0%) 605 (93.4%)
Related (p = 0.914) 46 (7.2%) 45 (6.9%)
Serious (p = 0.005) 354 (55.4%) 409 (63.1%)
Related serious (p = 0.249) 0 3 (0.55%)
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The aim of this section is to estimate the cost-effectiveness of palivizumab for 
immunoprophylaxis of RSV in high-risk children 
or particular subgroups of children at even higher 
risk. This section contains two components: 
(1) systematic review and analysis of published 
economic evaluations and reviews of economic 
evaluations; (2) economic analysis of palivizumab 
using a decision model developed by the authors.
Systematic review of 
economic evaluations
Methods
Search strategy
A comprehensive search for literature on the cost 
and cost-effectiveness of palivizumab versus no 
prophylaxis for immunoprophylaxis of RSV in 
high-risk children was conducted.
Studies on costs, quality of life, cost-effectiveness 
and modelling were identified from the following 
sources:
bibliographic databases: MEDLINE (Ovid), •	
1950 to January, week 3, 2007; EMBASE 
(Ovid), 1980 to 2007, week 03; Cochrane 
Library (Wiley internet version) [NHS 
Economic Evaluation Database (EED) and 
Database of Abstracts and Reviews of Effects], 
2006, Issue 4; and Office of Health Economics 
Health Economic Evaluation Database 
(HEED), January 2007 issue
internet sites.•	
Searches were not limited by date and there were 
no language restrictions. Details of search strategies 
can be found in Appendix 2.
Inclusion and exclusion criteria
Inclusion criteria applied for economic searches are 
summarised below.
Study design•	 : cost-effectiveness analysis, cost–
utility analysis or cost–benefit analysis.
Population•	 : children at high risk of 
hospitalisation, morbidity or death due to RSV 
infection.
Intervention•	 : immunoprophylaxis with 
palivizumab.
Comparator•	 : no prophylactic treatment.
Cost analysis was excluded.
Study selection and quality assessment
One reviewer applied the inclusion and exclusion 
criteria and extracted data. These were checked 
by a second reviewer. The quality of included 
primary economic evaluations was assessed using 
an adapted version of the Drummond criteria 
for economic evaluations.28 A modified version 
of the Oxman and Guyatt29 assessment tool and 
scale was used to assess the quality of reviews. 
Disagreements were resolved by discussion. The 
main characteristics, quality assessment and results 
of included economic evaluations were tabulated 
(see below).
Analysis
In order to make different ICERs comparable, 
they were converted from their currencies to 
pounds sterling (£) using an online currency 
converter.30 Once converted to pounds sterling, 
the cost data were inflated to 2006 prices using 
the NHS Executive Hospital and Community 
Health Services Pay and Prices inflation index.31 
For those studies that did not report price year, the 
incremental cost-effectiveness ratios were converted 
to pounds sterling using the rate in their study 
year.
Results of review of 
economic evaluations
The searches produced 240 citations, of which 207 
citations were excluded on the basis of the title 
and abstracts as they did not fulfil one or more of 
the inclusion criteria in terms of the population, 
the intervention or design of the studies. The 
full text was obtained for 33 citations for further 
assessment. Twelve studies were excluded. The 
details of the studies and reasons for exclusion are 
given in Appendix 5, Table 44. Twenty-one studies 
reached the final stage of our review and were 
considered for data extraction (Figure 5). Three 
of the included studies are systematic reviews of 
economic evaluations (Table 8) and the remaining 
Chapter 3  
Existing economic evaluations
Existing economic evaluations
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235 citations retrieved
by bibliographic
searches
33 citations for
which full text
were obtained
5 citations from the
internet
21 citations included in data
abstraction
3 systematic reviews
18 economic evaluations
207 citations excluded on the basis
of title or abstract on at least one
of the exclusion criteria
12 citations excluded after
reading paper
FIGURE 5 Flow chart of identification of existing economic evaluations.
18 are primary economic evaluation studies (Table 
9).
The quality of the systematic reviews was moderate: 
none assessed the quality of the included primary 
economic evaluation studies. Details of the quality 
assessments are given in Table 45 (see Appendix 
6). The three systematic reviews encompassed two, 
four and four primary economic evaluations that 
were identified in this report, respectively. All the 
reviews qualitatively summarised the results of the 
included economic evaluations and did not develop 
decision-analytical models to estimate the cost-
effectiveness of prophylaxis with palivizumab.
All the systematic reviews stated that the potential 
costs of palivizumab were far in excess of any likely 
savings achieved by decreasing hospital admission 
rates, and that palivizumab is not cost-effective 
when used in all children for whom it is licensed 
at a willingness-to-pay threshold of £60,000/QALY 
or less, and that continued use of palivizumab for 
very high risk children may be justified. Details 
of the main findings of the systematic reviews are 
summarised in Table 8.
The 18 primary economic evaluation studies 
included were assessed and found to be of 
variable quality. Most of the studies clearly 
defined questions and described the competing 
alternatives, correctly established clinical 
effectiveness, performed incremental analysis of 
both costs and consequences, and clearly presented 
the results. However, some studies did not identify 
all relevant costs and consequences and others 
did not accurately measure or value the costs and 
consequences. More than half of the included 
studies did not consider discounting of costs and 
consequences for differential timing adjustment. 
Most of the studies did not carry out an adequate 
sensitivity analysis. Fewer than half of the studies 
used a lifetime time horizon; others did not specify 
the time horizon or used a time horizon of 1 year. 
Half of the studies did not report the price year. 
Full details of the quality of assessments can be 
found in Table 47 (see Appendix 8).
The characteristics of the included primary 
economic evaluations are summarised in Table 9. 
Most studies performed cost-effectiveness or cost–
utility analyses, the remaining studies performed 
cost–benefit analysis. Most studies (n = 10) reported 
the ICER in terms of cost per hospital admission 
prevented (HAP), some studies (n =5 ) reported 
the incremental cost per life-year gained (LYG), 
and others (n = 4) reported the incremental cost 
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TABLE 8 Summary results of systematic reviews of economic evaluations
Study Country Population Intervention Comparator Main findings
Dunfield and 
Mierzwinski-Urban, 
200717 
Canada Premature 
children with or 
without CLD 
or children with 
CHD 
Palivizumab No prophylaxis The results of the included studies were variable; this may be due to different cost 
data sources
Palivizumab was not cost-effective when used in all children for whom it is 
recommended
Owing to the high cost of palivizumab, only children at very high risk of RSV 
should be administered palivizumab
Embleton et al., 200520 UK Premature infants 
with or without 
CLD
Palivizumab No prophylaxis None of the identified studies was a comprehensive economic analysis
All studies noted that true societal costs could not be addressed.
None of the UK cost studies showed economic benefit for palivizumab 
prophylaxis
The costs of prophylaxis were far in excess of any likely savings achieved by 
decreasing hospital admission rates
In the absence of a comprehensive economic assessment, continued use of 
palivizumab for high-risk children, such as those with CLD, may appear justified
Kamal et al., 200232 USA Premature infants 
with or without 
CLD
Palivizumab No prophylaxis The potential cost of palivizumab prophylaxis far exceeded the actual cost of 
hospitalisation
The reported divergent results may be explained by differences in the study 
methods, assumptions and the poor quality of some economic evaluations
Policy-makers, or providers or payers, need to critically appraise and judiciously 
interpret the cost-effectiveness of palivizumab
CHD, congenital heart disease; CLD, chronic lung disease.
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TABLE 9 Characteristics of included primary economic evaluations
Author Country Study design Population Female (%) Intervention Comparator Perspective Model Time horizon
Farina et al., 
200231
Argentina CEA Born at ≤ 35 weeks 
GA (≤ 6 months) or at 
≤ 28 weeks GA (≤ 12 
months) or CLD ≤ 2 
years
29 Palivizumab No prophylaxis Societal (stated, 
but not strictly)
Not specified 2 years
Numa, 200038 Australia CBA, CEA Born at ≤ 35 weeks GA 
(≤ 6 months) or CLD ≤ 2 
years
43 Palivizumab No prophylaxis Provider Not specified Not specified
Reeve et al., 
200635
Australia CEA Hospitalised children 
positive for RSV either 
born at < 33 weeks GA 
or with birth weight 
< 2500 g (and/or of 
indigenous origin or 
with siblings) or with 
CLD or CHD, ex-NICU
Not specified Palivizumab No prophylaxis Provider Not specified Not specified
Roeckl-
Wiedmann et 
al., 200336
Germany CEA Born at ≤ 35 weeks GA 
with or without CLD
0 Palivizumab No prophylaxis Societal Decision-
analytical model
1 year
Chiroli, 200537 Italy CEA CHD ≤ 2 years 46 Palivizumab No prophylaxis Third payer Decision-
analytical model
Life time
Vogel et al., 
200238 
New 
Zealand
CEA Born at ≤ 32 weeks GA Not specified Palivizumab No prophylaxis Societal Not specified Not specified
de Armentia, 
200339
Spain CEA Born at ≤ 32 weeks GA Not specified, 
about 50% 
because of 
cohort
Palivizumab No prophylaxis Health service Not specified 2 years
Lazaro et al., 
200640
Spain CUA Born at 32–35 weeks 
GA
Not specified Palivizumab No prophylaxis Provider, 
societal
Decision-
analytical model
Life time
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Author Country Study design Population Female (%) Intervention Comparator Perspective Model Time horizon
Raya et al., 
200618
Spain CEA Born at 32–35 weeks 
GA inclusive and two or 
more risk factorsa
Not specified Palivizumab No prophylaxis Hospital Decision-
analytical model
1 year
Simpson and 
Burls, 20019
UK CEA Born at ≤ 35 weeks GA 
(≤ 6 months), or CLD 
≤ 2 years
43 Palivizumab No prophylaxis Provider Decision-
analytical model
Lifetime
Nuijten et al., 
200725
UK CUA Born at ≤ 35 weeks GA 
(≤ 6 months), or CLD 
≤ 2 years or CHD ≤2 
years
43–46 Palivizumab No prophylaxis Provider, 
societal
Decision-
analytical model
Lifetime
Joffe, 199941 USA CEA Born at ≤ 36 weeks GA Not specified Palivizumab No prophylaxis Societal, 
clinician, policy-
maker
Decision-
analytical model
Lifetime
Lofland et al., 
200042 
USA CEA Born at ≤ 35 weeks GA 
(≤ 6 months) 
43 Palivizumab No prophylaxis Provider Decision-
analytical model
1 year
Stevens et al., 
200043
USA CEA Born at ≤ 32 weeks GA Not specified Palivizumab No prophylaxis Provider Not specified Not specified
Shireman and 
Braman, 200244
USA CBA Born during RSV season 
≤ 10 months 
39 Palivizumab No prophylaxis Provider Not specified 1 year
Strutton and 
Stang, 200345 
USA CEA Born at ≤ 35 weeks GA Not specified Palivizumab No prophylaxis Payer, societal Not specified Not specified
Yount et al., 
200446
USA CUA CHD ≤ 2 years 46 Palivizumab No prophylaxis Societal Decision-
analytical model
Life time
ElHassan et al., 
200647
USA CBA, CUA Hypothetical cohort of 
children born at 26–32 
weeks GA without CLD
Not specified Palivizumab No prophylaxis Societal Decision-
analytical model
1 year without 
asthma, 8 years 
with asthma
CEA, cost-effectiveness analysis; CBA, cost–benefit analysis; CLD, chronic lung disease; CUA, cost–utility analysis; GA, gestational age; NICU, neonatal intensive care unit; RSV, 
respiratory syncytial virus.
a Breast feeding for less than 2 months, age < 10 weeks at start of season, sibling of school age, live with four or more adults, family history of allergy.
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per quality-adjusted life-year (QALY). About half 
of the studies employed a societal perspective; 
others employed provider, or payer, or third-party 
perspectives.
The summary results of the included primary 
economic evaluations are given in Table 10.
The results of the included economic evaluation 
studies show that the ICERs vary from £5307/HAP 
to £69,240/HAP with mean of £33,190/HAP (SD 
£17,807/HAP), from £5288/LYG to £1,104,351/
LYG with mean £202,104/LYG (SD £78,066/LYG), 
and from £3,164/QALY to £1,489,668/QALY with 
mean £547,817/QALY (SD £169,082/QALY).
In the UK study by Simpson and Burls9 values of 
£55,000/HAP and £122,800/LYG were reported for 
preterm infants or children with CLD (less than 2 
years old). The most recent economic evaluation 
(2007) is a UK study by Nuijten et al.25 funded by 
the manufacturer of palivizumab. This reported 
ICERs of £25,800/LYG and £18,900/QALY for 
preterm infants or children (less than 2 years old) 
with CLD, and £7900/LYG and £7,500/QALY for 
children with CHD.
An analysis of existing 
economic evaluations
The ICERs vary a lot from study to study. This 
makes it difficult for decision-makers to decide 
whether prophylaxis with palivizumab is effective. 
In order to find what is driving the differences 
between the ICERs we looked at the results 
for systematic differences in the populations, 
interventions, metrics, outcomes, time horizons 
and other parameters. These differed; for example, 
doses of palivizumab used in the economic 
evaluations were different, varying from four to 
six, while two studies did not specify dose. Studies 
also used different perspectives: half of the studies 
estimated ICERs from a societal perspective and 
others from a provider or hospital perspective. The 
time horizons were different, most varying from 
1 year to 2 years, while two of the studies did not 
specify time horizon.
Population
The studies by Simpson and Burls9, Raya et al.18, 
Farina et al.33, Reeve et al.35, Roeckl-Wiedmann et 
al.36, Vogel et al.38, de Armentia39, Lofland et al.42 
and Stevens et al.43 assessed the cost-effectiveness of 
palivizumab in terms of cost per hospital admission 
prevented (HAP). Although the populations of 
these studies were preterm infants with gestational 
age less than 36 weeks, some studies reported 
cost-effectiveness for different subpopulations, 
such as preterm children with CLD and those 
born at different gestational ages, or with different 
risk factors, such as having a sibling in a day-care 
group. In general, prophylaxis with palivizumab 
was more cost-effective in those children with a 
higher risk of being admitted to hospital due to an 
RSV infection than in children from populations 
at lower risk. For example, Roeckl-Wiedmann et 
al.36 reported that the ICER for preterm children 
born at a gestational age of less than 35 weeks 
and without other risk factors was £162,800/
HAP and that the ICER for preterm children 
born at a gestational age of less than 35 weeks 
and with siblings in day-care groups was £42,200/
HAP. It can be seen that ‘having a sibling in day 
care’ contributed to the 74% ICER reduction. 
Discharge between October and December reduced 
the ICER to £20,200/HAP, contributing to the 
52% ICER reduction. CLD further reduced the 
ICER to £5300/HAP, contributing to the 74% of 
ICER reduction. Vogel et al.38 reported that CLD 
increased the ICER from £13,300/HAP to £27,000/
HAP for preterm children with a gestational age 
of less than 32 weeks, an increase of 103%, and 
from £40,600/HAP to £69,200/HAP for preterm 
children with a gestational age between 29 and 
31 weeks, an increase of 70%. Stevens et al.43 
showed that the ICER was less than £30,000/HAP 
for those who were born at a gestational age of 
below 31 weeks, but was £57,500/HAP for those 
born at between 31 and 32 weeks gestational 
age. These risk factors were reflected in the RSV 
hospitalisation rates. These are listed in Table 10. 
The values of ICERs decrease as the risk difference 
of RSV hospitalisation between no prophylaxis and 
palivizumab become large (shown in Figure 6).
Outcomes and other 
model parameters
The studies by Simpson and Burls9, Nuijten et al.25, 
Chiroli37, Joffe41 and Strutton and Stang45 assessed 
the cost-effectiveness of palivizumab in terms of 
cost per life-year gained. The cost-effectiveness for 
children with CHD was £4300/LYG in the study by 
Chiroli37 and £7900/LYG in the study by Nuijten 
et al.25. The two studies used the same provider 
perspective and the same RSV hospitalisation rates, 
which was obtained from the RCT by Feltes et al.12, 
the same time horizon. The study by Nuijten et al.25 
applied a discount of 3.5% and the price year was 
specified as 2003, whereas the study by Chiroli37 
did not specify the price year and did not apply 
discounting. The studies by Simpson and Burls9, 
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 TABLE 10 Summary of results of economic evaluationsw
Author Country 
Price 
Year
Number 
of doses
Discount 
rate (%)
Hospitalisation rates (%)
Population
Reported in 
price year
Converted to £ 
(sterling) 2006 Palivizumab
No 
prophylaxis
Farina et 
al., 200233
Argentina 2000 4 Not 
specified
10.71 23.8 Born at ≤ 35 weeks GA (≤ 6 months), or at 
≤ 28 weeks GA (≤ 12 months), or CLD ≤ 2 
years
$15,358/HAP £8000/HAP
Numa, 
200034
Australia Not 
specified
5 Not 
specified
4.8 10.6 Born at ≤ 35 weeks GA (≤ 6 months), or 
CLD ≤ 2 years, weight < 6.7 kg
A$27,786/HDS £14,400/HDSa
Born at ≤ 35 weeks GA (≤ 6 months), or 
CLD ≤ 2 years, weight ≥ 6.7 kg
A$55,572/HDS £28,900/HDSa
Reeve et 
al., 200635
Australia Not 
specified
5 Not 
specified
2.0 4.0 Hospitalised children positive for RSV or 
born at ≤ 33 weeks GA 
A$98,818/HAP £42,000/HAPa
2.3 4.4 Birth weight < 2500 g A$88,547/HAP £37,700/HAPa
2.2 5.0 Indigenous and birth weight < 2500 g A$73,294/HAP £31,200/HAPa
1.8 4.8 Birth weight < 2500 g and with siblings A$69,861/HAP £29,700/HAPa
2.3 5.1 E-NICU A$79,619/HAP £33,900/HAPa
Roeckl-
Wiedmann 
et al., 
200336
Germany 2000 5 No 
discounting
24 54 Born at ≤ 35 weeks GA with CLD, siblings 
in day-care groups and discharge between 
October and December
€6639/HAP £5300/HAP
10 23 Born at ≤ 35 weeks GA with siblings in day-
care groups and discharge between October 
and December
€25,288/HAP £20,200/HAP
6 12 Born at ≤ 35 weeks GA with siblings in day-
care groups
€52,838/HAP £42,200/HAP
2 3 Born at ≤ 35 weeks GA without CLD, 
siblings in day-care groups and discharge 
between October and December
€204,68/4HAP £162,800/HAP
Chiroli, 
200537
Italy 2004 5 No 
discounting
5.3 9.7 CHD ≤ 2 years €7186/LYG £4300/LYG
continued
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Author Country 
Price 
Year
Number 
of doses
Discount 
rate (%)
Hospitalisation rates (%)
Population
Reported in 
price year
Converted to £ 
(sterling) 2006 Palivizumab
No 
prophylaxis
Vogel et 
al., 200238 
New 
Zealand
2000 5 Not 
specified
Not specified 42.1 Discharged home on oxygen NZ$29,000/
HAP
£12,000/HAP
14.0 22.9 Born at ≤ 32 weeks GA, with CLD NZ$65,000/
HAP
£27,000/HAP
4.1 18.5 Born at ≤ 32 weeks GA, without CLD NZ$32,000/
HAP
£13,300/HAP
6.1 10 Born at 29–31 weeks GA, with CLD NZ$167,000/
HAP
£69,200/HAP
1.8 8.2 Born at 29–31 weeks GA, without CLD NZ$98,000/
HAP
£40,600/HAP
de 
Armentia, 
200339
Spain Unclear Unclear; 
up to 
50 mg, full 
five doses 
in total
N/A Unclear Born at ≤ 30 weeks GA €12,915/HAP £9500/HAP
Born at ≤ 32 weeks GA €20,900/HAP £15,400/HAP; 
appears to be 
data driven, states 
with 35 weeks 
GA, then treats 
only ≤ 32 weeks 
GA
Lázaro et 
al., 200640
Spain 2006 15 mg/
kg, mean 
of 3.88 
doses
3 1.8 8,1 Born at 32–35 weeks GA €4605/QALY  
(societal) 
£3200/QALY 
(societal)
€13,849/QALY 
(provider)
£9500/QALY 
(provider)
Raya et al., 
200618
Spain 2005 3.8 doses 
(mean), 
sharing 
vials
N/A 2.7 6.6 Born at 32–35 weeks GA €42,761/HAP 
to €68,104/
HAP
£29,400–46,800/
HAP
Simpson 
and Burls9
UK 2000 6 1.5 for 
benefit
4.8 10.6 Born at ≤ 35 weeks GA (≤ 6 months), or 
CLD ≤ 2 years
£43,000/HAP, 
£96,000/LYG
£55,000/HAP, 
£122,800/LYG
Nuijten et 
al., 200725
UK 2003 4.87 3.5 for 
both cost 
and benefit
4.8 10.6 Born at ≤35 weeks GA (≤ 6 months), CLD 
≤ 2 years
£16,720/QALY, 
£22,826/LYG
£18,900/QALY, 
£25,800/LYG
5.3 9.7 CHD ≤ 2 years £6664/QALY, 
£7002/LYG
£7500/QALY, 
£7900/LYG
TABLE 10 Summary of results of economic evaluations
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Author Country 
Price 
Year
Number 
of doses
Discount 
rate (%)
Hospitalisation rates (%)
Population
Reported in 
price year
Converted to £ 
(sterling) 2006 Palivizumab
No 
prophylaxis
Joffe, 
199941
USA 1995 4 3 for both 
cost and 
benefit
11.1 24.6 Born at 23–32 weeks GA, length of oxygen 
≥ 28 days, month of NICU discharge 
September to November
$33,000/LYG £30,400/LYG
4.8 10.7 Born at 23–32 weeks GA, length of oxygen 
≥ 28 days, month of NICU discharge 
December to August
$110,000/LYG £101,200/LYG
3.6 8 Born at 23–32 weeks GA, length of oxygen 
< 28 days, month of NICU discharge 
September to November
$160,000/LYG £147,200/LYG
1.4 3.1 Born at 23–32 weeks GA, length of oxygen 
< 28 days, month of NICU discharge 
December to August
$440,000/LYG £404,900/LYG
5.0 11 Born at 33–36 weeks GA, length of oxygen 
≥ 28 days, month of NICU discharge 
September to November
$110,000/LYG £101,200/LYG
2.0 4.4 Born at 33–36 weeks GA, length of oxygen 
≥ 28 days, month of NICU discharge 
December to August
$300,000/LYG £276,100/LYG
1.4 3.2 Born at 33–36 weeks GA, length of oxygen 
< 28 days, month of NICU discharge 
September to November
$430,000/LYG £395,700/LYG
0.5 1.2 Born at 33–36 weeks GA, length of oxygen 
< 28 days, month of NICU discharge 
December to August
$1,200,000/LYG £1,104,001/LYG
Lofland et 
al., 200042 
USA Not 
specified
5 Not 
specified
5b 10b Born at ≤ 35 weeks GA (≤ 6 months) $39,591/IEA 
if palivizumab 
therapy cost 
$2500
£31,300/IEAa 
if palivizumab 
therapy cost 
$2500
5b 10b $79,706/IEAa 
if palivizumab 
therapy cost 
$4500
£63,000/IEAa 
if palivizumab 
therapy cost 
$4500
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Author Country 
Price 
Year
Number 
of doses
Discount 
rate (%)
Hospitalisation rates (%)
Population
Reported in 
price year
Converted to £ 
(sterling) 2006 Palivizumab
No 
prophylaxis
Stevens et 
al., 200043
USA Not 
specified
5 Not 
specified
9.3 20.6 Born at ≤26 weeks GA $18,183/HAP £14,400/HAPa
6.6 14.6 Born at 27–28 weeks GA $24,113/HAP £19,100/HAPa
5.1 11.3 Born at 29–30 weeks GA $36,878/HAP £29,200/HAPa
2.9 6.4 Born at 31–32 weeks GA $72,712/HAP £57,500/HAPa
Shireman 
and 
Braman, 
200244
USA Not 
specified
Up to 6 Not 
specified
5.8 11.7 Born during RSV season ≤1 0 months Cost–benefit 
ratio 6.67:1, 
drug cost 
$4,687, 
hospitalisation 
cost decreased 
by $703
Cost–benefit 
ratio 6.67:1, drug 
cost £3746a, 
hospitalisation 
cost decreased by 
£559a
Strutton 
and Stang, 
200345 
USA 2002 Not 
specified
5 for both 
cost and 
benefit
Not specified Not specified Born at ≤ 35 weeks GA $66,200/LYG 
(societal)
£53,200/LYG 
(societal)
Not specified Not specified $66,400/LYG 
(payer)
£53,300/LYG 
(payer)
Yount et 
al., 200446
USA 2002 5 3 for both 
cost and 
benefit
5.3 9.7 CHD ≤ 2 years $114337/QALY £91,800/QALY
ElHassan 
et al., 
200647
USA 2002 5 3 for both 
cost and 
benefit
5.2 20.6 Hypothetical cohort of children born at 26 
weeks GA without CLD
$830,152/QALY £666,700/QALY
3.7 14.6 Hypothetical cohort of children born at 27 
weeks GA without CLD
$1,295,781/
QALY
£1,040,600/QALY
3.7 14.6 Hypothetical cohort of children born at 28 
weeks GA without CLD
$1,500,351/
QALY
£1,204,900/QALY
2.8 11.3 Hypothetical cohort of children born at 
29–30 weeks GA without CLD
$675,780/QALY £542,700/QALY
1.6 6.4 Hypothetical cohort of children born at 31 
weeks GA without CLD
$1,212,497/
QALY
£973,700/QALY
1.1 6.4 Hypothetical cohort of children born at 32 
weeks GA without CLD
$1,855,000/
QALY
£1,489,700/QALY
CHD, congenital heart disease; CLD, chronic lung disease; GA, gestational age; E-NICU, ex-neonatal care unit; HAP, hospital admission prevented; HDS, hospital day saved; IEA, 
infection episode avoided; LYG, life-year gained; NICU, neonatal intensive care unit; QALY, quality-adjusted life-year.
a Cost year was not clearly defined, assumed to be the same as study year.
b Incidence of RSV infection.
TABLE 10 Summary of results of economic evaluations
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Nuijten et al.25, Joffe41 and Strutton and Stang45 
estimated the cost-effectiveness of palivizumab for 
preterm children. The values of ICER varied from 
£25,800/LYG to £404,900/LYG. The minimum 
ICER was reported in the study by Nuijten et 
al.25 and the maximum ICER was reported in 
the study by Joffe.41 The main variation in the 
ICER was caused by gestational age and NICU 
discharge seasons, which were reflected by RSV 
hospitalisation rates. The values of ICERs decrease 
as the risk difference of RSV hospitalisation 
between no prophylaxis and palivizumab becomes 
large (shown in Figure 7).
Risk difference of RSV hospitalisation between no
prophylaxis and palivizumab
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FIGURE 7 Cost-effectiveness (£/LYG).
Mortality
The studies by Nuijten et al.25, Lázaro et al.40, 
Yount et al.46, and ElHassan et al.47 assessed the 
cost-effectiveness of palivizumab in terms of cost 
per QALY. The cost-effectiveness for children with 
CHD was £7500/QALY in the study by Nuijten et 
al.25 and £91,800/QALY in the study by Yount et 
al.46 The ICERs and the model parameters of the 
two studies are summarised in Table 11.
These two studies used the same RSV 
hospitalisation rates, a similar dose of palivizumab 
and the same time horizon. The differences 
Risk difference of RSV hospitalisation between no
prophylaxis and palivizumab
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FIGURE 6 Cost-effectiveness (£/HAP).
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TABLE 11 ICERs and the corresponding model parameters (children with CHD)
Author
Industry 
sponsored
Hospitalisation rates (%)
Population Time horizon
Discount 
rate (%)
Number 
of doses
Mortality 
rate (%) Perspective
Utility 
value
ICER  
(£/QALY)Palivizumab
No 
prophylaxis
Nuijten et 
al., 200725
Yes 5.3 9.7 CHD ≤ 2 years Lifetime 3.5 4.87 4.5 Provider 0.88–
0.95
7500
Yount et al., 
200446
No 5.3 9.7 CHD ≤ 2 years Lifetime 3 5 3 Societal 0.71 91,800
TABLE 12 ICERs and the corresponding model parameters (preterm infants without CLD or children with CLD)
Author
Industry 
sponsored
Hospitalisation rates (%)
Population Time horizon
Discount 
rate (%)
Number 
of doses
Mortality 
rate (%) Perspective
Utility 
value 
ICER  
(£/QALY)Palivizumab
No 
prophylaxis
Nuijten et 
al., 200725
Yes 4.8 10.6 Born at ≤ 35 weeks GA 
(≤ 6 months), CLD ≤ 2 
years
Lifetime 3.5 4.87 8.11 Provider 0.88–
0.95
18,900
ElHassan et 
al., 200647
No 5.2 20.6 Hypothetical cohort 
of children born at 26 
weeks GA without CLD
1 year without 
asthma, 8 years 
with asthma
3 5 Not 
considered
Societal 0.89–
0.92
666,700
3.7 14.6 Hypothetical cohort 
of children born at 27 
weeks GA without CLD
1 year without 
asthma
3 5 Not 
considered
Societal 0.89–
0.92
1,040,600
3.7 14.6 Hypothetical cohort 
of children born at 28 
weeks GA without CLD
1 year without 
asthma
3 5 Not 
considered
Societal 0.89–
0.92
1,204,900
2.8 11.3 Hypothetical cohort of 
children born at 29–30 
weeks GA without CLD
1 year without 
asthma
3 5 Not 
considered
Societal 0.89–
0.92
542,700
1.6 6.4 Hypothetical cohort 
of children born at 31 
weeks GA without CLD
1 year without 
asthma
3 5 Not 
considered
Societal 0.89–
0.92
973,700
1.1 6.4 Hypothetical cohort 
of children born at 32 
weeks GA without CLD
1 year without 
asthma
3 5 Not 
considered
Societal 0.89–
0.92
1,489,700
CLD, chronic lung disease; GA, gestational age; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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FIGURE 8 Cost-effectiveness (£/QALY).
between the two studies are that Yount et al.46 used 
a societal perspective, an RSV mortality rate of 
3% and a utility value of 0.71, whereas Nuijten et 
al.25 used a provider perspective, an RSV mortality 
rate of 4.5% and utility values of 0.88–0.95. The 
ICER values for preterm children compared with 
the risk difference of RSV hospitalisation, which 
were collected from two studies25,47, are shown 
in Figure 8. The study by Lázaro et al.40 was not 
included as the number of doses of palivizumab 
was too low (fewer than 4). In general, we can 
see that the values of ICERs decrease as the 
differences in RSV hospitalisation rates between 
no prophylaxis and palivizumab become large. 
However, there is an exception in the case of the 
study by Nuijten et al.25, as shown at point A in 
Figure 8. The ICERs and the model parameters of 
the two studies are summarised in Table 12. Apart 
from the different perspectives, hospitalisation 
rates and time horizon, compared with the study 
by ElHassan et al.47, the study by Nuijten25 assumed 
a higher mortality rate (8.11%). This is probably 
the main reason that Nuijten et al.25 reported a very 
low ICER value. Three observational studies24,48,49 
report mortality rates for children admitted to 
hospital because of RSV infection. Meta-analysis 
of these studies gives a mortality rate of 3.72% for 
RSV hospital admission, which is similar to the 
mortality rate of 3% used in the study by Yount et 
al.46
In order to evaluate the effect of the high mortality 
rate on the cost-effectiveness, we reconstructed 
the model described in the study by Nuijten et 
al.25 and ran it using different mortality rates. The 
results are summarised in Table 13. The ICER 
changes from £29,200/LYG for a mortality rate of 
7% to £195,500/LYG for a mortality rate of 1%, 
and changes from £20,200/QALY for a mortality 
rate of 7% to £41,700/QALY for a mortality rate 
of 1%. Note that the best estimate of mortality for 
premature children without CLD that we could find 
TABLE 16 The results of cost-effectiveness versus different mortality rates using the model by Nuijten et al.23
Mortality rate (%)
7 6 5 4 3 2 1
ICER (£/LYG) 29,200 33,800 40,300 50,000 66,200 98,500 195,500
ICER (£/QALY) 20,200 22,000 24,200 27,000 30,500 35,200 41,700
ICER, incremental cost-effectiveness ratio; LYG, life-year gained; QALY, quality-adjusted life-year.
Existing economic evaluations
26
is smaller than any shown here and therefore the 
probable cost/QALY will be in excess of £41,000. 
Therefore, even given the other very optimistic 
assumptions favouring palivizumab used by 
Nuijten and colleagues in their model, palivizumab 
would not reach conventional UK levels of cost-
effectiveness when a more representative mortality 
rate is used.
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Given the disparity of results of existing economic evaluations and the fact that 
none of the models was suitable for addressing 
the questions posed in this review, we decided 
to construct a de novo model, the Birmingham 
Economic Evaluation (BrumEE). This chapter 
provides details of the BrumEE developed by our 
team and used to evaluate the cost-effectiveness of 
prophylaxis with palivizumab compared with no 
prophylaxis.
Methods of the BrumEE
The model was designed to estimate, from 
the UK NHS and societal perspectives, the 
incremental costs and outcomes in terms of 
QALYs of prophylaxis with palivizumab compared 
with no prophylaxis. The model also attempts 
to incorporate uncertainty in probabilities, 
resource use and utilities by incorporating the 
input parameters of the model as probability 
distributions. These distributions are used in a 
Monte Carlo simulation in order for uncertainty 
in the results of the model to be presented. The 
model is developed using the R programming 
language (http://cran.r-project.org). All costs are 
presented in 2006 UK pounds sterling (£). Both 
costs and benefits are discounted at 3.5%.
Structure of the model
The model structure is shown in Figure 9. The 
model follows high-risk children for their first RSV 
season. The high-risk children are divided into two 
groups: those receiving palivizumab prophylaxis 
and those not receiving prophylaxis. Children in 
either group may develop an RSV infection and 
be admitted to hospital. A proportion of them will 
require admission to a paediatric intensive care 
unit, the rest are managed in a general paediatric 
ward. A small proportion of children die. A time 
horizon of lifetime is used to take into account the 
impact of palivizumab on long-term morbidity 
and mortality of RSV infection. Cost-effectiveness 
is measured in terms of £ per QALY and £ per 
life-year gained. Adverse events are not taken 
into account in the model as the clinical trials did 
not show any important differences between the 
palivizumab and placebo groups.12,16
We do not consider sequelae (such as asthma, 
recurrent wheezing) in the base-case model. The 
relationship between RSV infections and the 
development of wheezing and asthma in children 
has been the subject of much debate. Most previous 
cohort studies have failed to identify a link between 
early RSV infection and atopic asthma. Recent 
cohort studies have indicated that wheezing in 
early childhood is associated with an increased 
incidence of atopic asthma, but that this risk is not 
increased by RSV infections.50
Estimation of model 
pathway parameters
Prognostic factor studies in RSV
The limited RCT data (Tables 5 and 6) do not 
distinguish adequately between subgroups of risk 
within the ‘high-risk’ groups (e.g. groups defined 
by different gestational ages or age at the start of 
RSV season). It is therefore not possible to answer 
the core question of this review (For which high-risk 
subgroups may palivizumab be a cost-effective use 
of resources?) from the RCT data alone. Hence, 
supplementary evidence is needed to model 
different risk groups within the licensed indication.
Unfortunately, the scope of the commissioning 
brief does not permit us to undertake a full 
systematic review to look for studies about the 
development, course or outcome of infection 
in children with RSV so we took a pragmatic 
approach to seek the best available information. 
We systematically looked for prognostic studies 
identified during the search for the systematic 
review and undertook a further specific systematic 
search for prognostic studies (see Appendices for 
details). Based on scrutiny of title and abstract we 
selected those that were of most relevance to the 
current UK context and of highest quality. The 
studies selected as most relevant are summarised in 
Table 15.
Of these, the papers by Carbonell-Estrany et 
al.51,52 and Rietveld et al.53 were the most useful. 
All include large samples of children and use an 
appropriate method to investigate prognostic 
factors. Carbonell-Estrany et al.51 and Rietveld 
et al.53 estimate risk by gestational age (GA), 
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FIGURE 9 Base-case decision tree model for palivizumab versus no prophylaxis.
which is a particularly important component of 
risk, and allows consideration of this important 
subgroup in the model. Carbonell-Estrany et 
al. 52 report a similar study for children with 
higher gestational age (> 32 weeks) and, along 
with Rietveld et al.53, compare risk in children of 
different ages. Carbonell-Estrany et al.52 use birth 
age for this comparison, whereas Rietveld et al.53 
use post-conceptional age. These papers also 
reported a significant impact of CLD/BPD and of 
having siblings at school (SAS) on the risk of RSV 
hospitalisation.The ORs and their confidence 
intervals for key prognostic factors are sumarised in 
Table 14.
For modelling prognosis, we decided to use the 
estimates for GA, CLD and SAS from Carbonell-
Estrany et al.51 These estimates are comparable to 
the odds ratios (OR) reported in the other papers, 
but the OR for GA in Rietveld et al.53 is estimated 
by grouped GAs rather than as an OR/month, as 
in the Carbonell-Estrany et al. papers, and so is 
less flexible for modelling purposes; in addition, 
Rietveld et al.53 report ORs to only one decimal 
TABLE 14 Estimated ORs [and confidence intervals (CIs)] for key prognostic factors
Risk factor
Carbonell-Estrany et al., 
200051
Carbonell-Estrany et al., 
200452
Rietveld et al.,  
200653
Gestational age 0.85, 0.72–0.99/week – ≤ 28 weeks: 3.2 (2.1–4.8)
29–32 weeks: 2.8 (2.1–3.8)
33–34 weeks: 2.3 (1.8–3.0)
35–36 weeks: 1.6 (1.3–1.9)
37+ weeks: 1.0
Chronic lung disease 3.1 (1.22–7.91) – 2.2 (no CI reported)
Siblings at school 1.86 (1.01–3.4) – –
Age – 0.55 (0.33, 0.92) No BPD 0.8/month (0.8, 0.8) 
with BPD 0.9/month (0.9, 1.0)
BPD, bronchopulmonary dysplasia; CI, confidence interval.
Health Technology Assessment 2008; Vol. 12: No. 36
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
29
place, which introduces a high rounding error. 
Similarly, Carbonell-Estrany et al.52 report an OR 
only for age groups above and below 3 months, 
whereas Rietveld et al.53 report an OR of 0.8/month 
for post-conceptional age without BPD and 0.9/
month for post-conceptional age with BPD. The 
OR for birth age used in our prognostic model was 
0.8, obtained by considering ORs of the correct 
order of magnitude according to Rietveld et al.53 
but which also corresponded well to data from the 
other paper.54
Other significant prognostic factors reported by 
these papers include sex, birth weight, parents’ 
level of education and overcrowding at home. 
With additional resources it would be possible to 
build a more comprehensive prognostic model that 
includes these and other factors.
The risk of hospitalisation due to RSV was 
estimated for different subgroups, cross-tabulated 
by GA and age, using a simple Excel spreadsheet. 
The OR for a specific group compared with the 
reference group (GA = 28 weeks, age = 3 months, 
no CLD or SAS) was calculated using the ORs taken 
from the prognostic papers using the formula:
OR
subgroup 
=  
exp(−lnOR
GA
(28 − GA) − lnOR
age
(3 − age) +  
(CLD*lnOR
CLD
) + (SAS*lnOR
CLD
)
where CLD and SAS are indicator variables for the 
presence/absence of these risk factors.
Note that the lnORs for GA and age are included 
as negative terms because our model uses 
increasing risk with lower values than the reference 
(OR > 1), whereas the ORs in the papers are 
reported the other way around (OR < 1).
The absolute risk for each group was then 
calculated from an estimated baseline risk for 
the reference group of 15.1%, obtained from 
considering the empirical data from the UK 
study by Deshpande et al.55 An RSV-related 
hospitalisation rate of 12.5% was reported for 
children less than 6 months with a gestational 
age of less than 28 weeks. We assumed that this 
hospitalisation rate was obtained from children 
with a gestational age of 26 weeks, 27 weeks and 
28 weeks. The odds ratio of 0.85 was applied to 
gestational ages and the hospitalisation rate of 
children with a gestational age of 28 weeks was 
estimated to be 10.8%. The odds ratio of 0.8 was 
applied to birth ages and the hospitalisation rate of 
infants under 3 months with a gestational age of 28 
weeks was estimated to be 15.1%, which was used to 
estimate the hospitalisation rates for children with 
different gestational ages and different birth ages.
The average of the derived absolute risks of 
hospitalisation for different subgroups across 
gestational age and birth age is estimated to be 
11.3%. This is consistent with a hospitalisation rate 
of 10.6% reported in the RCT.16
Estimation of model pathway parameters
RSV hospitalisation for infants 
born at ≤ 35 weeks of gestation 
or children with CLD
The IMpact-RSV16 RCT was conducted for infants 
born at ≤ 35 weeks of gestation or children with 
CLD. The results of the study showed that monthly 
prophylaxis with palivizumab was associated 
with a 55% (95% CI 38–72%) reduction in RSV 
hospitalisation compared with no prophylaxis 
(Table 8). Significant reductions were observed in 
both children with CLD (39%, 95% CI 20–58%) 
and premature children without CLD (78%, 95% CI 
66–90%).16 The RSV hospitalisation rate was 4.8% 
for prophylaxis with palivizumab and 10.6% for no 
prophylaxis. These rates were used in our model 
(Table 16).
RSV hospitalisation for CHD children
One RCT study, by Feltes et al.,12 compared 
RSV hospitalisation rate in children with CHD 
receiving or not receiving prophylaxis with 
palivizumab. The results showed that monthly 
prophylaxis with palivizumab was associated 
with a 45% reduction in RSV hospitalisation rate 
(Table 5). RSV hospitalisation rates were 5.3% 
in the palivizumab group and 9.72% in the no 
prophylaxis group (Table 17). One Switzerland 
cohort study by Duppenthaler et al.24 has been 
identified for RSV hospitalisation rates in children 
< 24 months of age with CHD. This study reported 
that RSV hospitalisation rates in CHD patients 
less than 24 months of age varied from 0.5% to 
2.5%, which is fourfold lower than that reported 
from the RCT study. The latitude and location of 
Switzerland suggest that RSV seasons might be 
expected to be similar to those experienced in the 
UK. However, it is unclear whether demographic 
characteristics were the same between the cohort 
study and the RCT study (Tables 2 and 4). The 
RSV-hospitalisation rates obtained from the RCT 
study are used in the base case model. The RSV-
hospitalisation rates of 0.5% to 2.5% from the 
cohort study are used in sensitivity analysis. RSV-
hospitalisation rates of 5.6% for prophylaxis with 
palivizumab and 7.9% for no prophylaxis in the 
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TABLE 15 Prognostic studies
Reference Design Population Outcomes Factors Results
Arnold et al., 
199956
Prospective 
multicentre 
cohort
1516 children with lung 
disease (CLD, cystic 
fibrosis, and others) 
hospitalised with RSV, 
1993–1995 (159 only 
reported)
Duration of 
hospitalisation, ICU, 
duration of ICU, 
mechanical ventilation, 
duration of ventilation
CLD, cystic fibrosis, pneumonitis, pulmonary 
malformation, neurogenic disorders, 
tracheoesophageal fistula, other
No significant differences between groups; 
patients using home oxygen were more likely 
to be admitted to ICU (p = 0.03)
Carbonell-
Estrany et al., 
200051
Prospective 
multicentre 
cohort
680 children born ≤ 32 
weeks gestation, 1998–
1999 (584 evaluable)
Hospitalisation for RSV Gestational age, birth weight, family history 
of asthma, CRIB score, age at start of RSV 
season, month of discharge, CLD, heart 
disease, neurological disease, ventilation 
at birth, breast-feeding, smoke exposure, 
day care, one or more siblings, school-age 
siblings
Gestational age (OR 0.85, 0.72–0.99), 
chronic lung disease (OR 3.1, CI 1.22–7.91), 
school-age siblings (OR 1.86, CI 1.01–3.4)
Carbonell-
Estrany et al., 
200452
Prospective 
multicentre 
cohort
1832 children born at 
33–35 weeks gestation, 
2000–2002
Hospitalisation for RSV Multiple pregnancy, abnormal delivery, 
intubation, ICU at birth, ethnicity, month 
of birth, sex, small for gestational age, any 
chronic condition, crowding, two or more 
smokers at home, older siblings, preschool-
age siblings in day care and not breast-
feeding, eczema in a first-degree relative
Month of birth, sex, small for gestational 
age, any chronic condition, crowding, two 
or more smokers at home, older siblings, 
preschool-age siblings in day care and not 
breast-feeding, eczema in a first-degree 
relative
Clark et al., 
200057
Prospective 
multicentre 
cohort
656 high-risk children, 
1998–2000 (< 36 weeks 
gestation, < 24 months 
and discharged with 
supplemental oxygen)
Hospitalisation for RSV Prematurity, discharge with oxygen Premature infants at higher risk than those 
discharged with oxygen
Grimaldi et 
al., 200258
Prospective 
multicentre 
cohort
484 children admitted 
for RSV bronchiolitis, 
1999–2000
PICU admission in 
children hospitalised for 
RSV-induced bronchiolitis
Prematurity, low birth weight, RDS, 
mechanical ventilation, CLD, CHD
Prematurity, low birth weight, RDS, 
mechanical ventilation, CLD, CHD
Holberg et 
al., 199159
Prospective 
multicentre 
cohort
1,179 healthy children 
1980–1984
RSV-LRTI Breast feeding, maternal education, sex, 
shared bedroom, birth month, ethnicity, 
maternal smoking, day care
Breast feeding, sex, shared bedroom
Rietveld et 
al., 200653
Retrospective 
multicentre 
cohort
143,130 (2469 
hospitalised) children, 
1996–1998
Hospitalisation for RSV Sex, gestational age, birth weight, CLD, age Sex, gestational age, birth weight, CLD, age
Kneyber et 
al., 200060
Quantitative 
review
10 studies Asthma Asthma associated with RSV infection 40% vs 11% (p < 0.001) up to 5 years 
follow-up, 22% vs 10% (p = 0.19) 5–10 
years
CLD, chronic lung disease; CRIB, clinical risk index for babies; ICU, intensive care unit; LRTI, lower respiratory tract infection; PICU, paediatric intensive care unit; RDS, respiratory 
distress syndrome; RSV, respiratory syncytial virus.
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TABLE 16 Model pathway parameters for preterm infants without CLD or children with CLD
Parameter Estimate Source
RSV-related mortality rate (without CLD) 0.0043 Chater et al., 200661
RSV-related mortality rate (with CLD) 0.04  
(0.03–0.05)
Stensballe et al., 20035
Probability of ICU admission 0.107 Deshpande et al., 2003;55 Greenough et al., 2001;62 
Clark et al., 2000;57 Broughton et al., 200563
Relative risk of RSV hospitalisation rate between 
palivizumab versus no prophylaxis
0.4519 The IMpact-RSV Study Group, 199816
Probability of RSV hospitalisation in palivizumab 
prophylaxis group (without CLD)
0.018 The IMpact-RSV Study Group, 199816
Probability of RSV hospitalisation in palivizumab 
prophylaxis group (with CLD)
0.079 The IMpact-RSV Study Group, 199816
Probability of RSV hospitalisation in no prophylaxis 
group (without CLD)
0.081 The IMpact-RSV Study Group, 199816
Probability of RSV hospitalisation in no prophylaxis 
group (with CLD)
0.128 The IMpact-RSV Study Group, 199816
CLD, chronic lung disease; ICU, intensive care unit; RSV, respiratory syncytial virus.
TABLE 17 Model pathway parameters for children with CHD
Parameter Estimate Source
RSV-related mortality rate 0.0372 Wang et al., 1995;24 Moler et al., 1992;48 Navas et 
al., 199249
Probability of ICU admission 0.387 Feltes et al., 200312
Relative risk of RSV hospitalisation rate between 
palivizumab and no prophylaxis
0.5473 Feltes et al., 200312
Probability of RSV hospitalisation in palivizumab 
prophylaxis group
0.0532 Feltes et al., 200312
Probability of RSV hospitalisation in no prophylaxis 
group
0.0972 Feltes et al., 200312
ICU, intensive care unit; RSV, respiratory syncytial virus.
TABLE 18 Probability of ICU stay for preterm infants
Study N (RSV hospitalisation) N (ICU) %
Greenough et al., 200162 45 6 13.33
Clark et al., 200057 53 5 9.43
Broughton et al., 200563 44 4 9.09
Deshpande et al., 200355 53 6 11.32
Pooled result 10.71
ICU, intensive care unit; RSV, respiratory syncytial virus.
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cyanotic stratum, and 5% vs 11.8% in the acyanotic 
stratum reported from the RCT study are also used 
for sensitivity analysis.
Probability of ICU admission
Four UK studies, by Greenough et al.,62 Clark et 
al.,57, Broughton et al.63 and Deshpande et al.,55 
were meta-analysed to estimate the ICU rate. The 
individual and pooled results are shown in Table 18.
Feltes et al.14 reported that 13 out of 34 palivizumab 
recipients who were hospitalised due to RSV 
infection were admitted to the ICU, compared with 
24 out of 63 placebo recipients who were admitted 
to hospital because of RSV infection (Table 6). This 
gives an average ICU admission rate of 38.7% for 
CHD children. This is consistent with the ICU 
admission rate (38.2%) reported in the study by 
Chiroli.37
Mortality rates for children born ≤ 35 
weeks of gestation or children with CLD
Mortality rates of 0.4% in the prophylaxis with 
palivizumab group and 1% in the no prophylaxis 
group were reported in the RCT study (Table 6).16 
However, the study was not powered to estimate 
mortality rates25 because it was designed to 
evaluate RSV hospitalisation rates associated with 
prophylaxis with palivizumab and no prophylaxis. 
Furthermore, they are not the mortality rates 
required by the decision-analytical model. The 
model needs estimates of mortality rates for 
those who were admitted to hospital due to RSV 
infection. The mortality rates reported in the RCT 
are the total death rates for those in either arm. 
Therefore, these cannot be directly used in the 
model.
The study by Sampalis and Sampalis23 reported 
a mortality rate of 8.11% (196/2415) for RSV 
hospitalisation. This mortality rate in a cohort of 
children generally considered to be less high risk 
(32–35 weeks’ gestation) is exceptionally high, and 
is far greater than reported among more high-risk 
children. Moreover, this mortality rate is all-cause 
mortality during follow-up subsequent to RSV 
hospitalisation, and does not necessarily relate to 
RSV hospitalisation per se. The author reported a 
significantly higher rate of sudden or otherwise 
unexplained death among RSV-hospitalised 
children than among controls, possibly an artefact 
from the use of poorly coded, routinely collected 
discharge data or selection bias. Since the median 
age at RSV hospitalisation among the preterm 
cohort was 6.9 months, and as the risk of sudden 
infant death syndrome greatly reduces by 6 months 
of age, use of the mortality figure from this study 
for model estimates is inappropriate. Wang et 
al.24 reported RSV hospitalisation rates of 5.06% 
(4/79) for CLD and 3.38% (5/148) for gestation 
< 37 weeks. The subgroups in this study were not 
mutually exclusive, e.g. children with gestation 
< 37 weeks could also have had other risk factors 
such as CLD, cardiac disease, immunocompromise, 
etc. As the authors mentioned, there were only 
six deaths in the entire cohort of 689 hospitalised 
children; four of the children who died had 
underlying illnesses while one was premature 
and one was less than 6 weeks of age. Again, it is 
inappropriate to use these mortality rates in the 
model because it is not clear whether the deaths 
were due to RSV or to underlying disease.
The RSV-related mortality rate among preterm 
infants without CLD derived from the study by 
Chater et al.61 was 0.43%. Stensballe et al.5 reported 
high mortality rates of 3 –5% among children with 
CLD. Therefore, a mortality rate of 4% was used 
in the base-case model for preterm children with 
CLD.
Mortality rates for CHD children
The economic evaluation study by Yount et 
al.46 used a mortality rate of 3% for both the 
prophylaxis with palivizumab and no prophylaxis 
groups. The study by Nuijten et al.25 used a 
mortality rate of 4.5% for RSV hospitalisation. The 
RCT by Feltes et al.12 reported a total mortality rate 
of 3.3% for the palivizumab prophylaxis group 
and of 4.2% for the no prophylaxis group (Table 
6). They are not the mortality rates required by the 
decision-analytical model as the model requires 
mortality rates of those who were admitted to 
hospital because of RSV infection.
Three studies24,48,49 that reported a mortality rate 
for those who were admitted to hospital due to 
RSV infection were identified. The study by Moler 
et al.48 reported a mortality rate of 2.53% (2/79), 
that by Navas et al.49 a mortality rate of 3.46% 
(9/260) and that by Wang et al.24 a mortality rate 
of 5.26% (3/57). Meta-analysis of these studies 
gives a mortality rate of 3.72% for those who were 
admitted to hospital due to RSV infection. This 
value of the mortality rate was used in the base-case 
model for children with CHD (Table 17).
Resource use and costs
The UK NHS perspective is adopted for the 
base-case evaluation and the cost-effectiveness 
is expressed in terms of incremental cost per 
QALY or per LYG. In the non-base-case analysis, 
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we also include cost implications for a societal 
perspective which includes parent work loss costs 
due to infant’s hospitalisation or for administrating 
prophylaxis with palivizumab. Thus, the 
identification of costs for the model was conducted 
from both an NHS perspective and a societal 
perspective.
Medical costs
The utilisation of palivizumab reported in the study 
by Nuijten et al.25 is used in the base-case model. It 
was based on assumptions about the number of 50-
mg and 100-mg vials used in the RCT studies.12,16 
Among preterm infants without CLD or children 
with CLD, 38.7% used a 50-mg vial and 91.3% used 
a 100-mg vial. Among children with CHD, 39.6% 
of children used a 50-mg vial and 100% of infants 
used 100-mg vial; in 3.8% of cases a second 100-mg 
vial was used.25
The cost of a 50-mg vial of palivizumab is £360.40 
and the cost of a 100-mg vial of palivizumab is 
£600.10.64 The recommended dose of palivizumab 
is 15 mg/kg body weight administered once 
monthly throughout the RSV season. We assume 
that each infant received five doses. Palivizumab 
utilisation and unit cost for preterm infants are 
listed in Table 19 and for children with CHD in 
Table 20.
Administration costs
We assumed that palivizumab is routinely 
administered in a outpatient setting and that the 
costs of palivizumab administration consist of the 
following components:
8.4 min of GP time and 15 min of nurse time •	
at the first visit to see the patient and discuss 
RSV prophylaxis with palivizumab
15 min of nurse time in the following visits.•	
The resource use for palivizumab administration 
and unit cost for preterm infants are listed in Table 
19 and for children with CHD in Table 20.
Hospitalisation costs
The two RCT studies12,16 reported the number of 
patients who were admitted to paediatric wards 
and ICUs and the total of days in paediatric 
wards and in ICUs. For preterm infants without 
CLD or children with CLD, the average ICU stay 
is calculated to be 1.37 days and the average of 
non-ICU stay is calculated to be 6.47 days.25 Two 
UK cohort studies57,65 reported length of stay in 
hospital due to RSV infection. However, the study 
by Clark et al.57 reported only median of length 
of hospital stay (4 days with a range of 2–7 days), 
making it difficult to combine the length of stay 
in hospital with the RCT study. The other study 
TABLE 19 NHS perspective or societal perspective resource use and costs for preterm infants
Resource use Source Unit cost Source Total
Palivizumab Five doses; 38.7% 
50 mg, 91.3% 100 mg
Numa, 2000;34 
Chiroli, 2005;37 
Nuijten et al., 200725
£360.40/50 mg; 
£600.10/100 mg
BNF64 £3436.83
Palivizumab 
administration
1 × 8.4 min GP Yount et al., 200446 £2.45 Curtis and 
Netten, 200631
£20.58
Palivizumab 
administration
5 ×15 min nurse Yount et al., 200446 £0.52 Curtis and 
Netten, 200631
£39.00
Hospitalisation 
(intensive care unit)
1.37 days The IMpact-RSV 
Study Group, 199816 
£1723 Nuijten et al., 
200725
£3183.24
Hospitalisation (non-
intensive care unit)
6.47 days The IMpact-RSV 
Study Group, 199816
£492 Nuijten et al., 
200725
£2360.57
Parents’ work loss 
due to administration 
of prophylaxis 
5 × 3 hours Yount et al., 200446 £13.98 ONS;66 ESRC67 £209.70
Parents’ work loss 
due to children in 
hospital
7.84 × 8 hours The IMpact-RSV 
Study Group, 1998;16 
Yount et al., 200446
£13.98 ONS;66 ESRC67 £876.83
ESRC, Economic and Social Research Council; ONS, Office for National Statistics.
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TABLE 20 NHS perspective or societal perspective resource use and costs for children with CHD
Resource use Source Unit cost Source Total
Palivizumab Five doses, 39.6% 
50 mg, 100% 100 mg. 
3.8% 200 mg
Numa, 2000;34 Chiroli, 
2005;37 Nuijten et al., 
200725
£360.40/50 mg; 
£600.10/100 mg
BNF64 £3736.90
Palivizumab 
administration
1 × 8.4 min GP Yount et al., 200446 £2.45 Curtis and 
Nettern, 200631
£20.58
Palivizumab 
administration
5 × 15 min nurse Yount et al., 200446 £0.52 Nuijten et al., 
200725
£39.00
Hospitalisation 
(intensive care unit)
6.14 days The IMpact-RSV Study 
Group, 199816
£1723 Nuijten et al., 
200725
£10,579.22
Hospitalisation 
(non-intensive care 
unit)
6.25 days The IMpact-RSV Study 
Group, 199816
£492 Nuijten et al., 
200725
£3075
Parents’ work 
loss due to 
administration of 
prophylaxis 
5 × 3 hours Yount et al., 200446 £13.98 ONS;66 ESRC67 £209.70
Parents’ work loss 
due to children in 
hospital
12.39 × 8 hours The IMpact-RSV Study 
Group, 1998;16 Yount 
et al., 200446
£13.98 ONS;66 ESRC67 £1385.70
ESRC, Economic and Social Research Council; ONS, Office for National Statistics.
by Thomas et al.65 reported a total of 26 ICU 
days for three RSV-positive admissions and three 
admissions with RSV status unknown, but did not 
report the length of ICU stay for the three RSV-
positive patients, making it difficult to estimate 
the average ICU days for RSV admission. We used 
the average number of days in a paediatric ward 
and in ICU estimated from the RCTs in the model. 
The hospitalisation resource use and unit cost for 
preterm children are listed in Table 19. For children 
with CHD, the average ICU stay is calculated to 
be 6.14 days and the average non-ICU stay was 
calculated to be 6.25 days.25 The hospitalisation 
resource use and unit cost for children with CHD 
are listed in Table 20.
Parent work loss costs
Parent work loss costs consist of two parts, that 
due to the infant’s hospitalisation and that due 
to administrating prophylaxis with palivizumab. 
We assumed that in each case the infant was 
accompanied by one parent and that 3 hours 
of work was missed for each visit to administer 
palivizumab and 8 hours of work was lost in 
accompanying the infant to hospital.46 The weekly 
wage in the UK in 2002 was estimated to be 
£442,67 which is equivalent to £516.58 in 2006. 
The average number of hours worked in the UK is 
estimated to be 36.96 hours per week.66 This gives 
a unit cost of £13.98/hour for estimating parent 
work loss cost. The parent work loss and unit costs 
for preterm children are listed in Table 19 and for 
children with CHD in Table 20.
Estimation of QALYs
Life expectancy
National statistics (1997–2001) reported average 
life expectancy to be 79.4, 77.8, 76.8, 74.6, 73.3, 
and 71 years for men and 82.2, 81.7, 81.3 79.3, 
78.6, and 77.6 year for women in different social 
classes.68 The life expectancy for children at risk 
of RSV infection is calculated by averaging the 
life expectancies for men and women in different 
social classes using the assumption that men and 
women are equally represented in each social 
group. The mean life expectancy is estimated to be 
77.8 with a standard deviation of 3.44. For preterm 
infants without CLD or children with CLD, the 
life expectancy at the age of 1 year was assumed to 
be 76.8 years. In the case of children with CHD, 
95.3% of children were predicted to be survived 
to age 16 years if they had survived to age of 1 
year.25,69 Therefore, life expectancy at the age of 1 
year was assumed to be 76.1 years for children with 
CHD.
Utilities
The study by Greenough et al.70 assessed the 
health-related quality of life (HRQoL) for 
preterm children at the age of 5 years using the 
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Health Utilities Index (HUI). The HUI describes 
a family of generic health status and HRQoL 
measures. Parents were sent the HUI2/3 and 
asked to complete the 15 questions to reflect their 
child’s health over the previous 4 weeks. The 
HUI2 measures seven attributes of health status 
describing 24,000 unique health states, while HUI3 
describes 972,000 unique health states. The HUI2 
was originally developed for paediatric application 
and clinical evaluation studies, whereas HUI3 was 
developed for use in adults and population surveys. 
The median HUI2 multiattribute utility function 
was 0.88 (range 0.16–1.00) in the RSV-positive 
children, while the median HUI2 multiattribute 
utility function was 0.95 (range 0.03–1.00) in the 
non-RSV-positive children. The median HUI 3 
multiattribute scores were 0.93 (range –0.05 to 
1.00) for RSV-positive children and 0.97 (range 
–0.32 to 1.00) for non-RSV-positive children. 
These utility values are used in the model for 
preterm children with or without CLD and are 
listed in Table 21. As mentioned above, the utility 
estimate was made by asking parents (rather than 
children themselves) to complete the questions to 
reflect their child’s health. This might introduce 
a bias in utility estimate. However, because the 
utility estimates for children hospitalised for RSV 
infection or not hospitalised for RSV infection were 
evaluated in the same way (i.e. parents completed 
the questionnaire) the effect of utility estimate 
made by parents for a child on the overall results is 
likely to be small and the conclusions unaltered.
Utility data for children and adults with CHD are 
lacking. The economic evaluation study by Yount et 
al.46 extrapolated data from congestive heart failure 
to the CHD population and used a utility of 0.71 
for children with CHD. We use the same utility 
values for children with CHD as those for preterm 
children with or without CLD (Table 21).
Assessment of cost-effectiveness 
using the base-case model
The results of cost-effectiveness are presented 
in three ways. Firstly, mean costs and QALYs for 
prophylaxis with palivizumab and no prophylaxis 
are presented and the incremental cost per QALY 
is calculated. For the base-case analysis, the 
incremental costs per LYG and per HAP are also 
presented. Secondly, cost-effectiveness–acceptability 
curves (CEACs) and scatterplots of incremental 
costs and outcomes generated from PSAs are 
presented. CEACs are used to illustrate uncertainty 
in results due to statistical variability around the 
parameter estimates. The curves demonstrate 
the likelihood that a strategy is cost-effective at 
different threshold values of willingness to pay for 
an additional QALY. The PSA is undertaken using 
appropriate distributions for all model variables. 
The model is run for 10,000 simulations. The 
results are summarised as the mean ICER for all 
simulations. Thirdly, the results of deterministic 
sensitivity analyses are presented for subgroups 
of the premature population and for specific RSV 
hospitalisation rates for children with CHD.
In order to consider the wider costs and benefits 
of prophylaxis with palivizumab to society, cost-
effectiveness analyses are also undertaken from a 
societal perspective, taking into account the cost of 
parent work loss.
Assessment of cost-effectiveness 
using an extended model
It can be seen from the results of using realistic 
mortality rate estimates as parameters in the 
industry-sponsored model by Nuijten et al.25 
(which makes other assumptions favourable to 
palivizumab, such as the 100% occurrence of 
asthma in children admitted to hospital) that 
palivizumab does not meet conventional UK levels 
of cost-effectiveness in all children who meet the 
licensed indication.
TABLE 21 Estimated utilities
Utility values
SourceRSV hospitalisation Not RSV hospitalisation
Preterm with or 
without CLD
0.88 0.95 Greenough et al., 2004;70 Nuijten et al., 200725 
Children with 
CHD
0.88 0.95 Greenough et al., 2004;70 Nuijten et al., 200725
CHD, congenital heart disease; CLD, chronic lung disease; RSV, respiratory syncytial virus.
The Birmingham Economic Evaluation
36
Nonetheless, if there were evidence that by 
preventing RSV hospitalisations we might reduce 
asthma morbidity, then this would improve the 
cost-effectiveness of palivizumab. Although there 
is no evidence to show a causal link between early 
RSV infection and atopic asthma, a recent cohort 
study showed that wheezing in early childhood is 
associated with an increased incidence of atopic 
asthma.50 It is difficult to know whether children 
who are prone to asthma are more likely to become 
symptomatic when infected by RSV or whether 
RSV may increase the risk of asthma. We found five 
studies60,71–74 that reported asthma/wheezing rates 
for children who were admitted to hospital due to 
RSV infection and children who were not admitted 
to hospital due to RSV infection. The follow-up 
period varied from 2 to 15 years. The pooled 
sequelae rates were 0.23 for RSV hospitalisation 
and 0.12 for non-hospitalisation, giving a pooled 
odds ratio (OR) of 2.3 (95% CI 1.74–3.02). The 
studies suffered from various biases.
Because our clinical experts advised us that it was 
more likely that children prone to asthma were 
likely to get more symptomatic RSV infections 
rather than RSV infections causing asthma, 
we decided not to include asthma in our base-
case model. Therefore, in order to model the 
possible effect of including increased asthma as 
a consequence of RSV infection, we undertook 
a separate analysis. To do this the BrumEE was 
RSV hospitalisation
RSV hospitalisation
No RSV hospitalisation
No RSV hospitalisation
Palivizumab
No prophylaxis
High-risk children
Sequela
NoIntensive care unit
Intensive care unit
Alive
Dead
Sequela
No
Alive
Dead
Sequela
No
Alive
Dead
Sequela
No
Alive
Dead
No intensive care unit
No intensive care unit
FIGURE 10 The extended decision tree model (taking sequelae into account).
extended to take sequelae (asthma/wheezing) into 
account. The structure of the extended model is 
shown in Figure 10.
Sequelae-associated costs
The study by Greenough et al.62 compared the 
health care utilisation of children with CLD who 
had or had not been admitted to hospital with a 
proven RSV infection. A total of 235 children with a 
median gestational age of 27 weeks was included in 
this study. Forty-five of them had at least once been 
admitted to hospital for a proven RSV infection. 
The health care utilisation and the corresponding 
unit costs for children with proven RSV infection 
are shown in Table 22.
The sequelae-associated cost for those who were 
admitted to hospital due to RSV infection is 
estimated based on the health care utilisation of the 
children with a proven RSV infection and adjusted 
by subtracting the first-year RSV hospitalisation 
cost from the calculated 2-year costs.
Results of the BrumEE
Cost-effectiveness results 
using a deterministic model
The costs and outcomes for preterm infants 
without CLD, children with CLD and children with 
CHD are listed in Tables 23, 24 and 25  respectively.
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TABLE 22 Resource use and costs of RSV hospitalisation (over 2 years)
Resource use Source Unit cost Source Total
Days in hospital 39.8 Greenough et al., 200162 £237 Nuijten et al., 200725 £9433
Days in ICU 2.9 Greenough et al., 200162 £1723 Nuijten et al., 200725 £4997
Days in paediatric 
ward
30.7 Greenough et al., 200162 £492 Nuijten et al., 200725 £15104
Outpatients paediatric 
attendance
11.9 Greenough et al., 200162 £148 Nuijten et al., 200725 £1761
GP contacts 16.3 Greenough et al., 200162 £22 Curtis and Netten, 
200631
£352
Community care 
contacts
28.2 Greenough et al., 200162 £30 Nuijten et al., 200725 £846
Consultations with GP 
for respiratory illness
8.3 Greenough et al., 200162 £22 Curtis and Netten, 
200631
£179
ICU, intensive care unit; RSV, respiratory syncytial virus.
TABLE 23 Average costs and outcomes for prophylaxis in preterm infants without CLD
Parameters Palivizumab No prophylaxis Cost difference Outcome difference
Costs
Drug £3437
Drug administration (GP) £21
Drug administration (nurse) £39
Hospital £67 £301
Total cost (NHS) £3564 £301 £3263
Sequelae £279 £1255
Total cost (NHS), including sequelae £3843 £1556 £2287
Parent work loss £226 £72
Total cost (societal) £3790 £373 £3417
Total cost (societal), including 
sequelae
£4069 £1628 £2441
Outcomes
No discounting life-year lost 0.0059 0.0267 0.0208
No discounting QALYs 76.3141 76.2934 0.0207
Discounting life-year lost 0.0021 0.0094 0.0073
Discounting QALYs 26.5163 26.5092 0.0072
CLD, chronic lung disease; QALY, quality-adjusted life-year.
Table 26 presents the cost-effectiveness results of the 
deterministic analysis using the base-case model 
(with no sequelae). The ICERs between prophylaxis 
with palivizumab and no prophylaxis are £454,100/
QALY for preterm infants without CLD, £63,800/
QALY for children with CLD and £79,800/QALY 
for children with CHD from the NHS perspective.
In order to compare the results from the BrumEE 
with previous decision-analytical models, we also 
present the ICERs per LYG. These are, from an 
NHS perspective, £446,100/LYG for preterm 
infants without CLD, £62,600/LYG for children 
with CLD, and £78,400/LYG for children with 
CHD, as shown in Table 27.
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TABLE 24 Average costs and outcomes for prophylaxis in preterm children with CLD
Parameters Palivizumab No prophylaxis Cost difference Outcome difference
Costs
Drug £3437
Drug administration (GP) £21
Drug administration (nurse) £39
Hospital £293 £475
Total cost (NHS) £3790 £475 £3315
Sequelae £1180 £1912
Total cost (NHS), including sequelae £4970 £2387 £2583
Parent work loss £283 £120
Total cost (societal) £4073 £595 £3478
Total cost (societal), including 
sequelae
£5253 £2507 £2746
Outcomes
No discounting life-year lost 0.2427 0.3932 0.1505
No discounting QALYs 76.0788 75.9292 0.1496
Discounting life-year lost 0.0853 0.1382 0.0529
Discounting QALYs 26.4346 26.3826 0.0520
CLD, chronic lung disease; QALY, quality-adjusted life-year.
TABLE 25 Average costs and outcomes for prophylaxis in children with CHD
Parameters Palivizumab No prophylaxis Cost difference Outcome difference
Costs
Drug £3714
Drug administration (GP) £21
Drug administration (nurse) £39
Hospital £382 £697
Total cost (NHS) £4155 £697 £3458
Sequelae £799 £1461
Total cost (NHS), including sequelae £4954 £2158 £2796
Parent work loss £287 £140
Total cost (societal) £4442 £837 £3605
Total cost (societal), including 
sequelae
£5241 £2298 £2943
Outcomes
No discounting life-year lost 0.1506 0.2752 0.1246
No discounting QALYs 75.4704 75.3466 0.1238
Discounting life-year lost 0.0533 0.0974 0.0441
Discounting QALYs 26.4156 26.3722 0.0434
CHD, congenital heart disease; QALY, quality-adjusted life-year.
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TABLE 26 Cost-effectiveness (£/QALY) results of the base-case model (NHS perspective)
Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
Preterm infants and children without CLD
No prophylaxis £301 26.5092
Palivizumab £3563 £3262 26.5163 0.0071 £454,100
Preterm infants and children with CLD
No prophylaxis £475 26.3826
Palivizumab £3789 £3314 26.4346 0.0520 £63,800
CHD children
No prophylaxis £697 26.3722
Palivizumab £4155 £3458 26.4156 0.0433 £79,800
CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
TABLE 27 Cost-effectiveness (£/LYG) results of the base-case model (NHS perspective)
Strategy Cost Cost difference LYGs LYG difference ICER (£/LYG)
Preterm infants and children without CLD
No prophylaxis £301 0.0094
Palivizumab £3563 £3262 0.0021 0.0073 446,100
Preterm infants and children with CLD
No prophylaxis £475 0.1382
Palivizumab £3789 £3314 0.0853 0.0529 62,600
CHD children
No prophylaxis £697 0.0974
Palivizumab £4155 £3458 0.0533 0.0441 78,400
CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; LYG, life-year gained.
TABLE 28 Cost-effectiveness (£/HAP) results of the base-case model (NHS perspective)
Strategy Cost Cost difference HAPs HAPs difference ICER (£/HAP)
Preterm infants and children without CLD
No prophylaxis £301 0.081
Palivizumab £3563 £3262 0.018 0.0063 51,800
Preterm infants and children with CLD
No prophylaxis £475 0.128
Palivizumab £3789 £3314 0.079 0.049 67,600
CHD children
No prophylaxis £697 0.0972
Palivizumab £4155 £3458 0.0532 0.0440 78,600
CLD, chronic lung disease; HAP, hospital admission prevented; ICER, incremental cost-effectiveness ratio.
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The ICERs for using palivizumab compared with 
no prophylaxis are £51,800/HAP for preterm 
infants without CLD, £67,600/HAP for children 
with CLD and £78,600/HAP for children with CHD 
(Table 28).
From a societal perspective, the ICERs for using 
palivizumab compared with no prophylaxis are 
£475,600/QALY for preterm infants without CLD, 
£66,900/QALY for children with CLD and £83,200/
QALY for children with CHD, as shown in Table 29.
Deterministic sensitivity analysis of 
cost-effectiveness (NHS perspective)
For preterm infants without CLD, deterministic 
sensitivity analyses were carried out with different 
mortality rates of 0.0005, 0.0013, 0.0073 and 
0.0811. The cost-effectiveness results are shown in 
Table 30. The results show that prophylaxis with 
palivizumab for preterm infants without CLD 
becomes more cost-effective as the RSV-related 
mortality rate increases. When the mortality rate 
of 8.11% (used in the study by Nuijten et al.25) is 
applied, the ICER is £24,100/QALY, which is below 
the UK cost-effectiveness threshold (£30,000/
QALY).
For children with CLD, deterministic sensitivity 
analyses were carried out with different mortality 
rates of 0.03 and 0.05. The cost-effectiveness 
results are shown in Table 31. The results show 
that prophylaxis with palivizumab for children 
with CLD becomes more cost-effective as the RSV-
related mortality rate increases. However, none 
of the ICERs reaches the UK cost-effectiveness 
threshold (£30,000/QALY).
TABLE 29 Cost-effectiveness (£/QALY) results of the base-case model (societal perspective)
Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
Preterm infants without CLD
No prophylaxis £372 26.5092
Palivizumab £3789 £3417 26.5163 0.0071 475,600
Children with CLD
No prophylaxis £596 26.3826
Palivizumab £4074 £3478 26.4346 0.0520 66,900
CHD children
No prophylaxis £838 26.3722
Palivizumab £4442 £3604 26.4156 0.0433 83,200
CHD, congenital heart disease; CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; QALY, quality-
adjusted life-year.
Table 32 shows the cost-effectiveness results for 
subpopulations of children with CHD. The ICER 
for prophylaxis with palivizumab versus no 
prophylaxis for children with cyanotic CHD is 
£159,400/QALY, which reflects the fact that the 
RSV hospitalisation rates are not significantly 
different between children with cyanotic CHD 
who do and those who do not receive prophylaxis 
with palivizumab. The ICER for prophylaxis with 
palivizumab compared with no prophylaxis for 
among with acyanotic CHD is £49,100/QALY, 
which is also above the conventional UK cost-
effectiveness threshold.
Sensitivity analyses are carried out using the RSV 
hospitalisation rates of 0.5–2.5% reported in the 
cohort study by Duppenthaler et al.26 for children 
with CHD. Figure 11 shows the sensitivity analysis 
results of cost-effectiveness as RSV hospital 
admission rate in the no prophylaxis group 
changes. The ICER is £123,300/QALY with a RSV 
hospital admission rate of 0.5% and £91,000/QALY 
with a RSV hospital admission rate of 2.5%.
Table 33 shows the cost-effectiveness for children 
with CHD at different birth ages. The RSV 
hospitalisation rates reported in the study by Boyce 
et al.75 were used (shown in Table 33). The value 
of ICER is £63,300/QALY for children with CHD 
at aged 0–6 months, £126,000/QALY for children 
aged 6–12 months and £457,900/QALY for 
children aged 12–24 months.
Cost-effectiveness (extended model 
in NHS and societal perspective)
Table 34 shows the cost-effectiveness results for 
preterm infants and children with CHD using 
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TABLE 30 Cost-effectiveness with different mortality rates for preterm infants without CLD (the base-case model, NHS perspective)
Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
Mortality rate = 0.0005
No prophylaxis £301 26.5173
Palivizumab £3563 £3262 26.5182 0.0009 3,905,500
Mortality rate = 0.0013
No prophylaxis £301 26.5156
Palivizumab £3563 £3262 26.5178 0.0022 1,502,100
Mortality rate = 0.0043
No prophylaxis £301 26.5092
Palivizumab £3563 £3262 26.5163 0.0071 454,100
Mortality rate = 0.0073
No prophylaxis £301 26.5027
Palivizumab £3563 £3262 26.5149 0.0122 267,500
Mortality rate = 0.0811
No prophylaxis £301 26.3442
Palivizumab £3563 £3262 26.4797 0.1355 24,100
CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
TABLE 31 Cost-effectiveness with different mortality rates for children with CLD (the base-case model, NHS perspective)
Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
Mortality rate = 0.03
No prophylaxis £475 26.4166
Palivizumab £3789 £3314 26.4556 0.0390 85,000
Mortality rate = 0.04
No prophylaxis £475 26.3826
Palivizumab £3789 £3314 26.4346 0.0520 63,800
Mortality rate = 0.05
No prophylaxis £475 26.3487
Palivizumab £3789 £3314 26.4137 0.0650 51,000
CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
TABLE 32 Cost-effectiveness for subpopulations of children with CHD (the base-case model, NHS perspective)
Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
CHD, cyanotic, hospitalisation rates = 0.056/0.079 (palivizumab/no prophylaxis)
No prophylaxis £567 26.3902
Palivizumab £4175 £3608 26.4128 0.0226 159,400
CHD, acyanotic, hospitalisation rates = 0.050/0.118 (palivizumab/no prophylaxis)
No prophylaxis £847 26.3518
Palivizumab £4132 £3285 26.4187 0.0669 49,100
CHD, congenital heart disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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FIGURE 11 ICERs vary as RSV hospital admission rate changes.
TABLE 33 Cost-effectiveness with different mortality rates for children with CHD (the base-case model, NHS perspective)
Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
Age 0 to < 6 months, hospitalisation rate = 0.1208
No prophylaxis £861 26.3498
Palivizumab £4245 £3384 26.4033 0.0535 63,300
Age 6 to < 12 months, hospitalisation rate = 0.0635
No prophylaxis £456 26.4054
Palivizumab £4023 £3567 26.4337 0.0283 126,000
Age 12 to < 24 months, hospitalisation rate = 0.0182
No prophylaxis £131 26.4500
Palivizumab £3845 £3714 26.4581 0.0081 457,900
CHD, congenital heart disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
TABLE 34 Cost-effectiveness (£/QALY), taking sequelae into account (NHS perspective)
 Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
Preterm infants without CLD
No prophylaxis £1556 26.5092
Palivizumab £3843 £2287 26.5163 0.0071 318,200
Children with CLD
No prophylaxis £2387 26.3826
Palivizumab £4970 £2583 26.4346 0.0520 49,700
Children with CHD 
No prophylaxis £2158 26.3722
Palivizumab £4954 £2796 26.4156 0.0433 64,600
CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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TABLE 38 Cost-effectiveness (£/QALY), taking sequelae into account (societal perspective)
Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
Preterm infants without CLD
No prophylaxis £1628 26.5092
Palivizumab £4069 £2441 26.5163 0.0071 339,700
Children with CLD
No prophylaxis £2507 26.3826
Palivizumab £5253 £2746 26.4346 0.0520 52,800
Children with CHD
No prophylaxis £2298 26.3722
Palivizumab £5241 £2943 26.4156 0.0433 67,900
CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
the extended model (with consideration of 
sequelae) from the NHS perspective. The ICER for 
prophylaxis with palivizumab versus no prophylaxis 
for preterm infants without CLD is £318,200/QALY. 
The ICER for prophylaxis with palivizumab versus 
no prophylaxis for children with CLD is £49,700/
QALY. The ICER for prophylaxis with palivizumab 
versus no prophylaxis for children with CHD is 
£64,600/QALY. These results demonstrate that 
prophylaxis with palivizumab for children with 
or without CLD tends to decrease ICER when 
sequelae are taken into account.
Table 35 shows the cost-effectiveness results for 
preterm infants and children with CHD using the 
extended model from societal perspective. The 
ICER for prophylaxis with palivizumab versus no 
prophylaxis for preterm infants without CLD is 
£339,700/QALY. The ICER for prophylaxis with 
palivizumab versus no prophylaxis for children with 
CLD is £52,800/QALY. The ICER for prophylaxis 
with palivizumab versus no prophylaxis for 
children with CHD is £67,900/QALY. These results 
demonstrate that prophylaxis with palivizumab for 
children with CHD tends to have a decreased ICER 
when potential sequelae are taken into account.
Cost-effectiveness results using 
a PSA (NHS perspective)
The incremental cost-effectiveness plane for 
prophylaxis with palivizumab compared with no 
prophylaxis for preterm infants without CLD is 
shown in Figure 12 (the parameter values and their 
distributions used in this analysis are given in Table 
48 in Appendix 9). This shows that, although the 
cost of palivizumab is always much higher than 
the cost of no prophylaxis, it always increases the 
QALY. The cost-effectiveness acceptability curve 
(CEAC) in Figure 13 shows that, compared with 
no prophylaxis, palivizumab has a probability of 
50% of having an ICER below £460,000/QALY, 
a probability of 10% of having an ICER below 
£320,000/QALY and a probability of 90% of having 
an ICER below £690,000/QALY.
The incremental cost-effectiveness plane for 
prophylaxis with palivizumab compared with 
no prophylaxis for children with CLD is shown 
in Figure 14 (the parameter values and their 
distributions used in this analysis are shown in Table 
49 in Appendix 9). This also shows that the cost 
of prophylaxis with palivizumab is always much 
higher than the cost of no prophylaxis and always 
increases the QALY. The CEAC in Figure 15 shows 
that, compared with no prophylaxis, palivizumab 
has a probability of 50% of having an ICER below 
£64,000/QALY, a probability of 10% of having an 
ICER below £48,000/QALY and a probability of 
90% of having an ICER below £86,000/QALY.
The incremental cost-effectiveness plane for 
prophylaxis with palivizumab compared with 
no prophylaxis for children with CHD is shown 
in Figure 16 (the parameter values and their 
distributions used in this analysis are shown in Table 
50). It demonstrates that the cost of prophylaxis 
with palivizumab is always much higher than the 
cost of no prophylaxis, and that in most cases 
prophylaxis with palivizumab increases the QALY. 
The CEAC in Figure 17 shows that, compared with 
no prophylaxis, palivizumab has a probability of 
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FIGURE 12 Incremental cost-effectiveness plane for prophylaxis with palivizumab compared with no prophylaxis for preterm infants 
without CLD. The line represents the £30,000/QALY willingness-to-pay threshold.
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FIGURE 13 Cost-effectiveness–acceptability curve for prophylaxis with palivizumab compared with no prophylaxis for preterm infants 
without CLD.
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FIGURE 14 Incremental cost-effectiveness plane for prophylaxis with palivizumab compared with no prophylaxis for children with CLD. 
The line represents the £30,000/QALY willingness-to-pay threshold.
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FIGURE 15 Cost-effectiveness–acceptability curve for prophylaxis with palivizumab compared with no prophylaxis for children with 
CLD.
The Birmingham Economic Evaluation
46
Incremental QALYs
Inc
rem
en
tal
 co
st (
£)
0 0.040.02 0.06 0.10 0.140.08 0.12 0.16
0
3000
1000
2000
4000
6000
5000
FIGURE 16 Incremental cost-effectiveness plane for prophylaxis with palivizumab compared with no prophylaxis for children with CHD. 
The line represents £30K/QALY willingness to pay threshold.
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FIGURE 17 Cost-effectiveness acceptability curve for prophylaxis with palivizumab compared with no prophylaxis for children with 
CHD.
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TABLE 36 Average ICER from PSA
Strategy Cost Cost difference QALYs QALY difference ICER (£/QALY)
Preterm infants without CLD
No prophylaxis £299 26.3239
Palivizumab £3555 £3256 26.3310 0.0072 454,100
Children with CLD
No prophylaxis £477 26.2079
Palivizumab £3789 £3312 26.2595 0.0517 64,100
Children with CHD
No prophylaxis £693 26.1997
Palivizumab £4166 £3473 26.2423 0.0427 81,400
CHD, chronic heart disease; CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted 
life-year.
50% of having an ICER below £85,000/QALY, 
a probability of 10% of having an ICER below 
£50,000/QALY and a probability of 90% of having 
an ICER below £158,000/QALY.
As can be seen above, the deterministic model gives 
similar but slightly lower estimates for the ICERs 
for palivizumab compared with no prophylaxis 
than the median willingness-to-pay threshold of the 
PSA. The best summary estimate for policy-makers 
from the latter type of analysis (which incorporates 
more of the uncertainty than does a deterministic 
model with sensitivity analyses) is currently 
considered to be the average ICER from the PSA. 
These are summarised in the Table 36 and again are 
very similar. A comparison of the estimates from 
the different methods is given in Table 37.
Results for PSA for subgroups 
with different risk factors
Gestational and birth ages
The cost-effectiveness for children with different 
risk factors was analysed. The most important 
risk factors for hospitalisation are gestational age, 
chronological age at the start of the RSV season 
and the presence of CLD or CHD. We therefore 
used the BrumEE to produce four economic 
evaluations – one for infants under 6 months old 
who are premature; one for children up to the age 
of 2 who have CLD; one for children up to the age 
of 2 who have siblings in day-care groups; and one 
for children up to the age of 2 who have CLD and 
siblings in day-care groups – stratifying by the risk 
factors of chronological age and gestational age.
The incremental cost/QALY for children with 
only gestational age (less than 24 up to 34 weeks) 
and low birth age as risk factors is relatively high 
(shown in Table 38) – it is greater than £60,000/
QALY in all subgroups.
However the incremental cost/QALY fell when the 
additional risk factor of having CLD was added. 
Table 39 shows the cost-effectiveness spectrum 
for children with CLD. The ICERs are less than 
or equal to £30,000/QALY for infants under 6 
months and with a gestational age of less than 26 
weeks and for infants under 3 months and with a 
gestational age of less than 30 weeks. The values 
of ICER lie between £30,000/QALY and £40,000/
QALY for infants under 3 months of age with a 
gestational age of less than 30 weeks, for infants 
aged 3–6 months with a gestational age less than 
28 weeks and for infants up to 9 months old with a 
gestational age of less than 24 weeks.
Table 40 gives the cost-effectiveness spectrum for 
children who only have the added risk factor of 
having a sibling in a day-care unit or school. The 
value of the ICERs never falls below £50,000/QALY 
in any subgroup.
Table 41 shows the cost-effectiveness spectrum for 
children with both CLD and siblings in a day-care 
unit or at school. The values of ICERs were less 
than or equal to £30,000/QALY for infants under 
3 months and with a gestational age of less than 
35 weeks, for infants aged 3–6 months and with 
a gestational age of less than 30 weeks and for 
infants aged 6–9 months old and with a gestational 
age of less than 26 weeks.
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TABLE 37 Comparative ICERs from different methods of BrumEE
Incremental cost/QALY (£)
Strategy
Deterministic 
analysis
10% probability 
of effectiveness 
from PSA
50% probability 
of effectiveness 
from PSA
90% probability 
of effectiveness 
from PSA 
Average from 
PSA
Preterm infants without 
CLD 
454,000 320,000 460,000 690,000 454,000
Children with CLD 64,000 48,000 64,000 86,000 64,000
Children with CHD 80,000 50,000 85,000 158,000 81,000
CHD, chronic heart disease; CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; PSA, probabilistic 
sensitivity analysis; QALY, quality-adjusted life-year.
TABLE 38 Average incremental cost/QALY from PSA in infants without CLD
Gestational age (weeks)
Birth age (months) ≤ 24 24–26 26–28 28–30 30–32 32–34
< 3 102,000 136,000 196,000 270,000 361,000 530,000
3–6 197,000 270,000 357,000 529,000 753,000 954,000
6–9 360,000 526,000 751,000 954,000 1283,000 1922,000
CLD, chronic lung disease; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life-year.
ICER cost/QALY coding: all £60,000 and over.
TABLE 39 Average incremental cost/QALY from PSA in children with CLD 
Gestational age (weeks)
Birth age (months) ≤ 24 24–26 26–28 28–30 30–32 32–34
<3 12,000a 15,000a 19,000a 23,000a 31,000b 40,000b
3–6 19,000a 24,000a 31,000b 42,000c 54,000d 75,000e
6–9 31,000b 42,000c 54,000d 75,000e 105,000e 141,000e
9–12 59,000d 75,000e 105,000e 142,000e 213,000e 284,000e
12–15 105,000e 140,000e 213,000e 285,000e 430,000e 429,000e
15–18 211,000e 286,000e 432,000e 431,000e 862,000e 867,000e
18–21 429,000e 428,000e 862,000e 867,000e 859,000e ∞
21–24 864,000e 865,000e 864,000e ∞ ∞ ∞
CLD, chronic lung disease; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life-year.
ICER cost/QALY coding:
a  < £30,000
b  £30,000 to < £39,999
c  £40,000 to < £49,999
d  £50,000 to < £59,999
e  £60,000 and over.
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TABLE 40 Average ICER from PSA: children with siblings in day-care groups
Gestational age (weeks)
Birth age (months) ≤ 24 24–26 26–28 28–30 30–32 32–34
< 3 59,000a 80,000 108,000 145,000 198,000 267,000
3–6 108,000 146,000 198,000 269,000 404,000 531,000
6–9 212,000 294,000 403,000 525,000 751,000 958,000
9–12 402,000 527,000 752,000 947,000 1,280,000 1,925,000
12–15 752,000 947,000 1284,000 1,934,000 3,890,000 3,893,000
15–18 1275,000 1,931,000 3897,000 3,939,000 3,886,000 3,868,000
18–21 3882,000 3,915,000 3,896,000 3,883,000 ∞ ∞
21–24 3874,000 ∞ ∞ ∞ ∞ ∞
ICER, incremental cost-effectiveness ratio; PSA, probabilistic sensitivity analysis.
ICER cost/QALY coding:
a £50,000 to < £59,999; all others £60,000 and over.
Other risk factors
Although the patient population included in the 
licensed indication is clearly defined, it is clinically 
heterogeneous and includes children with very 
different risks of hospitalisation following RSV and 
the tables above show estimates of the probability 
of hospitalisation for birth, gestational age and 
having a sibling at school or day care.
However, there are other risk factors that further 
increase the probability that an infant will be 
TABLE 41 Average ICER from PSA: for children with CLD and siblings in day care 
Gestational age (weeks)
Birth age (months) ≤ 24 24–26 26–28 28–30 30–32 32–34
< 3 9000a 10,000a 12,000a 15,000a 19,000a 25,000a
3–6 13,000a 15,000a 19,000a 24,000a 33,000b 42,000c
6–9 19,000a 24,000a 33,000b 42,000c 59,000d 75,000e
9–12 33,000b 45,000c 58,000d 76,000e 105,000e 141,000e
12–15 59,000d 83,000e 105,000e 140,000e 212,000e 284,000e
15–18 105,000e 141,000e 214,000e 286,000e 430,000e 430,000e
18–21 213,000e 285,000e 428,000e 429,000e 863,000e 866,000e
21–24 430,000e 431,000e 867,000e 870,000e 859,000e ∞
CLD, chronic lung disease; ICER, incremental cost-effectiveness ratio; PSA, probabilistic sensitivity analysis.
ICER cost/QALY coding:
a  < £30,000
b £30,000 to < £39,999
c £40,000 to < £49,999
d £50,000 to < £59,999
e £60,000 and over.
hospitalised for RSV and which will reduce the 
incremental cost/QALY. Information on risk 
factors was taken from pragmatically selected 
high-quality studies. Only studies that included 
risk factors adjusted for gestational age or which 
included only patients within a narrow gestational 
age band were included. The additional factors 
are tabulated in Table 42, with information about 
the study from which the estimates are taken. It 
should be remembered that residual confounding 
is likely to influence the estimate of risk in these 
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TABLE 42 Risk factors for RSV hospitalisation other than chronological age and adjusted/controlled for gestational age
Study Description Risk factor Estimatea (95% Cl) 
Rietvald et al., 
200653
Retrospective population-based cohort study, 
the Netherlands, 2469 hospitalised out of 
140,661 children born 1996–1998
Male 1.4 (1.3–1.5)
Birth weight: ≤ 2500 g 1.7 (1.5–2.0)
Birth weight: 2501–3000 g 1.3 (1.1–1.4)
Boyce et al., 
200075
Retrospective cohort, July 1989 to June 1993, 
Tennessee, USA. RSV season defined as 
November to April. Children less than 3 years 
enrolled from birth. Used Medicaid data files 
in incidence density study with child years 
denominator, excess rate in influenza season 
subtracted
Condition other than BPD or 
CHD
2.3 (2.1–2.6)
≥ 1 sibling 1.4 (1.3–1.5)
Male 1.3 (1.2–1.4)
White race (Tennessee, USA) 1.3 (1.2–1.4)
Rural residence (Tennessee, USA) 1.3 (1.2–1.4)
Maternal smoking 1.3 (1.2–1.4)
Maternal education ≤ 12 years 1.2 (1.1–1.3)
Figueras-Aloy, 
200476
Prospective case–control study, 50 Spanish 
hospitals, October 2002 to April 2003, cases 
33–35 gestational age at birth hospitalised for 
RSV (186), controls born at same time, 33–35 
gestational age 
History of wheezing in family 1.90 (1.19–3.01)
School-age siblings (≥ 1) 2.85 (1.88–4.33)
≥ 4 residents and visitors 
(excluding school-age siblings and 
subject
1.91 (1.19–3.07)
Breast feeding ≤ 2 months 3.26 (1.96–5.42)
Smoking, day care not significant
Law, 200477 Prospective cohort (PICNIC), 16 Canadian 
regions, November 2000 to June 2001, 
November 2001 to June 2002, following 
children born November to April at 33–35 
weeks GA, no RSV prophylaxis. 1862 children
Born in November, December or 
January
4.88 (2.57–9.29)
Male 1.91 (1.10–3.31)
Small for gestational age 2.19 (1.14–4.22)
Subject attending day care 12.32 (2.56–59.34)
Any preschool-age siblings 2.76 (1.51–5.03)
≥ 2 smokers in the household 
[OR1.71 (95% CI 0.97–3.00)], 
> 5 individuals in the home 
(including subject), eczema in 
first-degree relative not significant
Carbonell-
Estrany, 
200178
Cohort of 1206 children born at ≤ 32 weeks 
from April 1999 to April 2000.
School-age siblings 1.64 (1.05–2.55)
Tobacco smoke exposure 1.63 (1.05–2.56)
BPD, bronchopulmonary dysplasia; CHD, chronic heart disease; CI, confidence interval. GA, gestational age; OR, odds 
ratio; RSV, respiratory syncytial virus.
a Odds ratio from multiple logistic regression except Boyce (Poisson regression, incidence rate ratio).
observational studies. Where potential risk factors 
are associated with each other, the choice of factors 
entered into the model will influence the factors 
included in the final model. Further risk factors 
for RSV hospitalisation identified consistently 
in the included studies were male gender and 
intrauterine growth retardation/lower birth weight 
(as lower birth weight is a risk factor independent 
of gestational age, it is an indicator of relatively 
poor intrauterine growth). There were inconsistent 
results for maternal smoking. Other risk factors 
appeared only in one study, for example breast 
feeding for 2 months or less and November, 
December or January birthday: this reflects the 
different selection of variables for inclusion in 
multivariate models in the studies. It should be 
remembered that factors identified as important in 
one society will not necessary have the same impact 
in other settings; for example, the impact of race 
and rural residence may be different in northern 
Europe and the southern USA.
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These risk factors have not been formally included 
in the BrumEE as, without further work to identify 
relevant studies systematically, review their quality, 
extract data, consider whether pooling of estimates 
would be appropriate and to evaluate further risk 
stratification, there is the risk of reducing the 
accuracy and precision of the model estimates to 
an unacceptable degree. However, the presence 
of additional risk factors may be important in 
making the clinical decision as to whether to offer 
palivizumab prophylaxis to a particular baby as 
they increase the risk of hospitalisation. We think 
that it may not be inappropriate for a clinician 
to treat a child who has two or more or these 
additional risk factors as falling into a band of cost-
effectiveness that is one level more cost-effective 
than shown in Table 38 and, possibly, a child who 
has most or all or these risk factors as falling in a 
band that is two levels more cost-effective.
Summary
The assessment group developed a decision •	
tree with Monte Carlo simulation model to 
assess the cost-effectiveness of prophylaxis with 
palivizumab, compared with no prophylaxis. 
The model has been designed to estimate costs, 
from a UK NHS perspective and a societal 
perspective, and outcomes in terms of QALYs, 
for a lifetime time horizon.
According to this model, prophylaxis with •	
palivizumab is not a cost-effective strategy 
for preterm infants and children with CHD 
compared with no prophylaxis from both an 
NHS perspective and societal perspective. 
These findings are robust to probabilistic and 
other sensitivity analyses.
Prophylaxis with palivizumab is also not a cost-•	
effective strategy for preterm infants or infants 
with CLD who have no other risk factors.
Subgroup analyses showed that prophylaxis •	
with palivizumab for children with CLD may be 
cost-effective, at a willingness-to-pay threshold 
of £30,000/QALY, in
infants under 3 months old at the start of •	
the RSV season who were born at 30 weeks 
gestational age or less
infants under 6 months old at the start of •	
the RSV season who were born at 26 weeks 
gestational age or less.
Further analyses showed that prophylaxis •	
with palivizumab for children with CLD, and 
who also have a sibling in day care or school, 
may be cost-effective, at a willingness to pay 
threshold of £30,000/QALY, in
infants under 3 months old at the start of •	
the RSV season who were born at 35 weeks 
gestational age or less
infants under 6 months old at the start •	
of the RSV season who born at 30 weeks 
gestational age or less
infants under 9 months old at the start •	
of the RSV season who born at 26 weeks 
gestational age or less.
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Clinical effectiveness
Two good-quality trials provide evidence of the 
effectiveness of palivizumab in reducing the rate of 
RSV hospitalisation and RSV hospitalisation days 
in premature (≤ 35 weeks) infants and children with 
CLD and in children aged up to 2 years with CHD. 
Palivizumab appears to be safe and well tolerated.
Subgroup analysis suggested that palivizumab 
may be more effective in premature babies than 
in children with CLD. The reduction in RSV 
hospitalisation was greater in children with non-
cyanotic rather than cyanotic CHD, but in this case 
there was no convincing evidence from subgroup 
analysis that the effect sizes were different.
Three systematic reviews9,17,20 assessed the clinical 
effectiveness of palivizumab based on the two 
RCTs. They gave the same conclusion: palivizumab 
is effective for the prevention of RSV infection in 
infants and children who are at high risk.
Cost-effectiveness
We have identified three systematic reviews and 
18 primary studies for economic evaluations of 
prophylaxis with palivizumab.
The three systematic reviews on cost-effectiveness 
analysis came to similar conclusions. The study 
by Dunfield and Mierzwinski-Urban17 stated that 
the results of the included economic evaluation 
studies were variable due to different cost data 
sources, and that palivizumab was not cost-effective 
when used in all for whom it is recommended. 
Dunfield and Mierzwinski-Urban17 concluded that 
only children with a very high risk of RSV should 
be administered palivizumab owing to the high 
cost of palivizumab. The study by Embleton et 
al.20 reported that none of the identified studies 
was a comprehensive economic analysis and that 
the costs of prophylaxis were far in excess of any 
likely savings achieved by decreasing hospital 
admission rates and concluded that continued use 
of palivizumab for high-risk infants, such as those 
with CLD, may appear justified in the absence of a 
comprehensive economic assessment. The study by 
Kamal et al.32 reported that divergent results may 
be explained by differences in the study methods, 
assumptions and the poor quality of some 
economic evaluations and that the potential cost 
of palivizumab prophylaxis far exceeded the actual 
cost of hospitalisation; therefore, policy-makers, 
or providers, or payers need to critically appraise 
and judiciously interpret studies reporting the cost-
effectiveness of palivizumab.
Four primary studies9,25,41,45 reported cost-
effectiveness in terms of cost/LYG for preterm 
children with or without CLD. To make 
comparisons, we converted all ICERs into the UK 
pounds sterling at equivalent 2006 prices.
The ICERs varied from £25,800/LYG to £404,900/
LYG:
Two studies•	 25,37 reported cost-effectiveness in 
terms of cost per LYG for children with CHD, 
with ICERs varying from £5300/LYG to £7900/
LYG.
Three studies•	 25,40,47 reported cost-effectiveness 
in terms of cost per QALY for preterm children 
with or without CLD, with ICERs varying from 
£3200/QALY to £1,489,700/QALY.
Two studies•	 16,46 reported cost-effectiveness 
in terms of cost per QALY for children with 
CHD, with ICER varying from £7500/QALY to 
£68,700/QALY.
Other studies assessed cost-effectiveness in terms 
of cost/HAP for preterm children with or without 
CLD. The ICER varied from £5300/HAP to 
£69,200/HAP.
We have developed a decision-analytical model, 
the BrumEE, to assess the cost-effectiveness of 
prophylaxis with palivizumab.
The BrumEE shows that the ICERs for prophylaxis 
with palivizumab compared with no prophylaxis are 
£454,100/QALY for preterm infants without CLD, 
£63,800/QALY for children with CLD and £79,800/
QALY for children with CHD, from an NHS 
perspective. The base-case model also shows that 
the ICERs between prophylaxis with palivizumab 
and no prophylaxis are £446,100/LYG for preterm 
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infants without CLD, £62,600/LYG for children 
with CLD and £78,400/LYG for children with CHD 
from and NHS perspective, and that the ICERs 
between prophylaxis with palivizumab and no 
prophylaxis are £51,800/HAP for preterm infants 
without CLD, £67,600/HAP for children with CLD 
and £78,600/HAP for children with CHD from an 
NHS perspective. The similar cost-effectiveness 
results have been obtained from a societal 
perspective (£475,600/QALY for preterm infants 
without CLD, £66,900/QALY for children with 
CLD and £83,200/QALY for children with CHD). 
The probabilistic sensitivity analyses have shown 
that, compared with no prophylaxis, prophylaxis 
with palivizumab for preterm infants without CLD 
has a probability of 50% of having an ICER below 
£460,000/QALY, that prophylaxis with palivizumab 
for children with CLD has a probability of 50% of 
having an ICER below £64,000/QALY, and that 
prophylaxis with palivizumab for children with 
CHD has a probability of 50% of having an ICER 
below £85,000/QALY.
Strengths and limitations
The strengths of the assessment group economic 
model include the following aspects.
Firstly, the cost-effectiveness of prophylaxis •	
with palivizumab has been assessed in the time 
horizon of lifetime and expressed in terms of 
cost per LYG and cost per QALY (rather than 
in a 1-year time horizon and expressed only in 
cost per HAP, as in most previous models).
Secondly, the mortality rates for those who •	
admit to hospital due to RSV infection have 
been synthesised from meta-analysis of the 
available published evidence.
Thirdly, analysis was conducted from both an •	
NHS and a societal perspective.
Finally, in addition to the base-case model, an •	
extended model was used to assess the cost-
effectiveness of prophylaxis with palivizumab 
when sequelae are taken into account.
The assessment group model has the following 
limitations.
There is limited availability of good-quality •	
scientific evidence to inform some of the 
parameters and some studies have quite a 
varied range of estimates.
Evidence to inform the parameters of the •	
model were sought and selected pragmatically 
rather than through a systematic review.
The cost of sequelae was derived from only one •	
study. It was estimated by subtracting the first-
year cost due to RSV hospital admission from 
the total 2-year costs from a cohort study. The 
extended model was built with an assumption 
that the yearly sequelae costs are the same over 
several years.
The utility values for children with CHD were •	
assumed to be the same as those for preterm 
infants without CLD or children with CLD.
Only one RSV season was considered in the •	
models.
The premature infants or children with CLD/•	
CHD were assumed to have a normal full life 
expectancy.
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Implications for decision 
and policy-making
Prophylaxis with palivizumab is clinically effective 
for the prevention of serious LRTI caused by RSV 
infection and requiring hospitalisation in high-risk 
children. This conclusion is based on two RCTs: the 
IMpact-RSV study16 found a 55% of reduction in 
RSV hospitalisation among preterm infants without 
CLD or children with CLD; and the Feltes et al.12 
study found a 45% reduction in RSV hospitalisation 
for children with CHD. There is some evidence 
that prophylaxis may be particularly effective in 
premature infants.
In terms of cost-effectiveness, prophylaxis with 
palivizumab does not represent good value based 
on any willingness-to pay-threshold below £60,000/
QALY (the current UK ICER threshold is about 
£30,000/QALY) when used unselectively in preterm 
infants without CLD or children with CLD or CHD. 
This conclusion is in consistent with most previous 
economic evaluation studies, especially when only 
a short-term effect of RSV infection is considered 
(e.g. ICER is expressed as cost per HAP). However, 
our base-case model does show that prophylaxis 
with palivizumab may be cost-effective for some 
subgroups, such as young preterm infants with 
CLD.
The cost-effectiveness of prophylaxis with 
palivizumab is affected by the cost of palivizumab, 
and the length of stay and sequelae that 
RSV infection might have, in addition to the 
hospitalisation and mortality rates of RSV 
infection.
Suggested research priorities
Future research should be directed towards the 
following.
The body of evidence of the cost-effectiveness of 
prophylaxis with palivizumab is conditional on 
the quality of clinical evidence. Future research 
should focus on the major uncertainties in cost-
effectiveness identified by the BrumEE, particularly 
in RSV-related mortality rate, and the length of 
effect of RSV infection on morbidity and mortality 
in the UK settings. Further large observational 
studies are desirable for the estimate of the 
mortality rate for children with CLD or preterm 
infants without CLD and who are admitted to 
hospital because of RSV infection. The health-
related quality of life for RSV-infected children 
was assessed in the previous studies by measuring 
seven attributes of health status describing 24,000 
unique health states for preterm children at the age 
of 5 years. Long-follow-up (> 5 years) observational 
studies will be useful for the estimate of the health-
related quality of life and the period for which 
RSV infection has an effect on morbidity and 
mortality. In the first instance, a systematic review 
would more clearly identify gaps in knowledge and 
would inform the design of observational studies. 
A systematic review of the prognostic factors 
for hospital admission should be undertaken to 
permit the development of clinical guidelines to 
enable clinicians to identify the most appropriate 
children to be treated with palivizumab. Questions 
that could usefully be addressed in such research 
include:
What are the prognostic factors for hospital •	
admission due to RSV infection?
What are the risks of these prognostic factors •	
for hospital admission due to RSV infection?
Questions that could usefully be addressed in 
the systematic review and further observational 
research if the review confirmed that this was 
needed include:
What is the mortality rate for children with •	
CLD or preterm infants without CLD who are 
admitted to hospital due to RSV infection?
What is the health-related quality of life for •	
children with CLD or preterm infants without 
CLD who are admitted to hospital due to RSV 
infection?
What is the health-related quality of life for •	
children with CLD or preterm infants without 
CLD who are not admitted to hospital due to 
RSV infection?
What is the health-related quality of life for •	
children with CHD who are admitted to 
hospital due to RSV infection?
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What is the health-related quality of life for •	
children with CHD who are not admitted to 
hospital due to RSV infection?
For how long does RSV infection have an effect •	
on morbidity and mortality in children with or 
without CLD or CHD?
The BrumEE models suggest that prophylaxis 
with palivizumab may be cost-effective for some 
subgroups, such as preterm infants with CLD. 
However, the hospital admission rates for these 
patient subgroups were obtained from subgroup 
analyses, and the mortality rates for these patient 
subgroups were assumed to be the same as those 
for the group considered as a whole. Future 
research should focus on the major uncertainties 
for patient subgroups, including preterm infants 
with different gestational ages. Further RCTs may 
be useful in estimating hospitalisation rates for 
children with CLD and/or who have a sibling in day 
care or at school, are under 6 months old at the 
start of the RSV season and who were born at 30 
weeks gestational age or less. Questions that could 
usefully be addressed in such research include:
What is the effect size of prophylaxis with •	
palivizumab in terms of hospitalisation rates 
for children with CLD and/or who have a 
sibling in day care or at school, and who 
are under 6 months old at the start of the 
RSV season and who were born at 30 weeks 
gestational age or less?
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Database: Ovid MEDLINE(R), 
1950 to March, Week 2, 2007
Search strategy
exp Respiratory Syncytial Virus, Human/or rsv.1. 
mp.
respiratory syncytial virus.mp.2. 
bronchiolitis.mp. or exp Bronchiolitis, Viral/3. 
or/1–34. 
palivizumab.mp.5. 
monoclonal antibod$.mp.6. 
exp Antibodies, Monoclonal/7. 
synagis.mp.8. 
exp Immunotherapy/or immunoprophylaxis.9. 
mp.
or/5–910. 
4 and 1011. 
(systematic adj review$).tw.12. 
(data adj synthesis).tw.13. 
(published adj studies).ab.14. 
(data adj extraction).ab.15. 
meta-analysis/16. 
meta-analysis.ti.17. 
comment.pt.18. 
letter.pt.19. 
editorial.pt.20. 
animal/21. 
human/22. 
21 not (21 and 22)23. 
11 not (18 or 19 or 20 or 23)24. 
or/12–1725. 
24 and 2526. 
Database: EMBASE(Ovid), 
1980 to 2007, week 12
exp Respiratory Syncytial Pneumovirus/or rsv.1. 
mp. or exp Bronchiolitis/
bronchiolitis.mp.2. 
respiratory syncytial virus.mp.3. 
or/1–34. 
palivizumab.mp. or exp PALIVIZUMAB/5. 
exp Monoclonal Antibody/or monoclonal 6. 
antibod$.mp.
synagis.mp.7. 
immunoprophylaxis.mp. or exp 8. 
IMMUNOPROPHYLAXIS/)
or/5–89. 
4 and 910. 
‘meta-analysis’/11. 
metaanalys$.ti,ab.12. 
meta-analys$.ti,ab.13. 
meta analys$.ti,ab.14. 
cochrane.ti,ab,de.15. 
(review$or overview$).ti,ab.16. 
(synthes$adj3 (literature$or research$or study 17. 
or studies or data)).mp.
pooled analy$.ti,ab.18. 
(systematic$adj2 review$).ti,ab.19. 
or/11–1920. 
10 and 2021. 
19 or 1122. 
10 and 2223. 
Cochrane Library (Wiley 
internet version), 2007, Issue 1
Search strategy
respiratory next syncytial#1 
rsv#2 
bronchiolitis#3 
MeSH descriptor Bronchiolitis, Viral, this #4 
term only
MeSH descriptor Respiratory Syncytial Virus, #5 
Human, this term only
(#1 OR #2 OR #3 OR #4 OR #5)#6 
immunoprophylaxis#7 
monoclonal next antibod*#8 
MeSH descriptor Antibodies, Monoclonal #9 
explode all trees
palivizumab#10 
(#7 OR #8 OR #9 OR #10)#11 
(#6 AND #11)#12 
Database: Ovid MEDLINE(R) in-
process and other non-indexed 
citations, 26 March 2007
Search strategy
respiratory syncytial virus.mp.1. 
bronchiolitis.mp. or exp Bronchiolitis, Viral/2. 
palivizumab.mp.3. 
monoclonal antibod$.mp.4. 
synagis.mp.5. 
xp Immunotherapy/or immunoprophylaxis.6. 
mp.
or/1–27. 
or/3–68. 
7 and 89. 
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Database: Ovid MEDLINE(R), 
1950 to March, Week 2, 2007
Search strategy
exp Respiratory Syncytial Virus, Human/or rsv.1. 
mp.
respiratory syncytial virus.mp.2. 
bronchiolitis.mp. or exp Bronchiolitis, Viral/3. 
or/1–34. 
palivizumab.mp.5. 
monoclonal antibod$.mp.6. 
exp Antibodies, Monoclonal/7. 
synagis.mp.8. 
exp Immunotherapy/or immunoprophylaxis.9. 
mp.
or/5–910. 
11. 4 and 1011. 
randomised controlled trial.pt.12. 
controlled clinical trial.pt.13. 
14. randomised controlled trials.sh.14. 
random allocation.sh.15. 
double-blind method.sh.16. 
single-blind method.sh.17. 
or/12–1718. 
(animals not human).sh.19. 
18 not 1920. 
clinical trial.pt.21. 
exp clinical trials/22. 
(clin$adj25 trial$).ti,ab.23. 
((singl$or doubl$or trebl$or tripl$) adj25 24. 
(blind$or mask$)).ti,ab.
placebos.sh.25. 
placebo$.ti,ab.26. 
random$.ti,ab.27. 
research design.sh.28. 
or/21–2829. 
29 not 1930. 
30 not 2031. 
comparative study.sh.32. 
exp evaluation studies/33. 
follow up studies.sh.34. 
prospective studies.sh.35. 
(control$or prospectiv$or volunteer$).ti,ab.36. 
or/32–3637. 
37 not 1938. 
38 not (20 or 31)39. 
20 or 31 or 3940. 
11 and 4041. 
from 41 keep 1–28042. 
Database: EMBASE (Ovid), 1980 
to 2007, week 12
Search strategy
exp Respiratory Syncytial Pneumovirus/or rsv.1. 
mp. or exp Bronchiolitis/
bronchiolitis.mp.2. 
respiratory syncytial virus.mp.3. 
or/1–34. 
palivizumab.mp. or exp PALIVIZUMAB/5. 
exp Monoclonal Antibody/or monoclonal 6. 
antibod$.mp.
synagis.mp.7. 
immunoprophylaxis.mp. or exp 8. 
IMMUNOPROPHYLAXIS/
or/5–89. 
4 and 910. 
randomised controlled trial/11. 
exp clinical trial/12. 
exp controlled study/13. 
or/11–1214. 
10 and 1415. 
Database: CINAHL (Cumulative 
Index to Nursing & Allied Health 
Literature), 1982 to March 2007
Search strategy
exp Respiratory Syncytial Viruses/or rsv.mp. or 1. 
exp Bronchiolitis/
respiratory syncytial virus.mp.2. 
bronchiolitis.mp.3. 
or/1–34. 
palivizumab.mp. or exp PALIVIZUMAB/5. 
monoclonal antibod$.mp.6. 
exp Antibodies, Monoclonal/7. 
synagis.mp.8. 
immunoprophylaxis.mp.9. 
immunotherapy.mp. or exp 10. 
IMMUNOTHERAPY/
or/5–1011. 
4 and 1112. 
exp CLINICAL TRIALS/13. 
12 and 1314. 
from 12 keep 1–11215. 
SCI (Web of Knowledge), 
1900 to 27 March 2007
Search terms
RSV or respiratory syncytial virus or bronchiolitis
palivizumab or synagis or immunoprophylaxis or 
monoclonal antibod*
random* or trial*
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Database: Ovid MEDLINE(R), 
1950 to January, week 3, 2007
Search strategy
exp Respiratory Syncytial Virus, Human/or rsv.1. 
mp.
respiratory syncytial virus.mp.2. 
bronchiolitis.mp. or exp Bronchiolitis, Viral/3. 
or/1–34. 
palivizumab.mp.5. 
monoclonal antibod$.mp.6. 
exp Antibodies, Monoclonal/7. 
synagis.mp.8. 
exp Immunotherapy/or immunoprophylaxis.9. 
mp.
or/5–910. 
4 and 1011. 
economics/12. 
exp ‘costs and cost analysis’/13. 
cost of illness/14. 
exp health care costs/15. 
economic value of life/16. 
exp economics medical/17. 
exp economics hospital/18. 
economics pharmaceutical/19. 
exp ‘fees and charges’/20. 
(econom$or cost or costs or costly or costing or 21. 
price or pricing or pharmacoeconomic$).tw.
(expenditure$not energy).tw.22. 
(value adj1 money).tw.23. 
budget$.tw.24. 
or/12–2425. 
11 and 2526. 
Database: Ovid MEDLINE(R), 
1950 to January, week 3, 2007
Search strategy
exp Respiratory Syncytial Virus, Human/or rsv.1. 
mp.
respiratory syncytial virus.mp.2. 
bronchiolitis.mp. or exp Bronchiolitis, Viral/3. 
or/1–34. 
palivizumab.mp.5. 
monoclonal antibod$.mp.6. 
exp Antibodies, Monoclonal/7. 
synagis.mp.8. 
exp Immunotherapy/or immunoprophylaxis.9. 
mp.
or/5–910. 
4 and 1011. 
decision support techniques/12. 
markov.mp.13. 
exp models economic/14. 
decision analysis.mp.15. 
cost benefit analysis/16. 
or/12–1617. 
11 and 1718. 
4 and 1719. 
18 or 1920. 
Database: Ovid MEDLINE(R), 
1950 to January, week 3, 2007
Search strategy
exp Respiratory Syncytial Virus, Human/or rsv.1. 
mp.
respiratory syncytial virus.mp.2. 
bronchiolitis.mp. or exp Bronchiolitis, Viral/3. 
or/1–34. 
palivizumab.mp.5. 
monoclonal antibod$.mp.6. 
exp Antibodies, Monoclonal/7. 
synagis.mp.8. 
exp Immunotherapy/or immunoprophylaxis.9. 
mp.
or/5–910. 
4 and 1011. 
quality of life/12. 
life style/13. 
health status/14. 
health status indicators/15. 
or/12–1516. 
4 and 1617. 
Database: EMBASE, 1980 
to 2007, week 03
Search strategy
exp Respiratory Syncytial Pneumovirus/or rsv.1. 
mp. or exp Bronchiolitis/
bronchiolitis.mp.2. 
respiratory syncytial virus.mp.3. 
or/1–34. 
palivizumab.mp. or exp PALIVIZUMAB/5. 
exp Monoclonal Antibody/or monoclonal 6. 
antibod$.mp.
synagis.mp.7. 
immunoprophylaxis.mp. or exp 8. 
IMMUNOPROPHYLAXIS/
or/5–89. 
4 and 910. 
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cost benefit analysis/11. 
cost-effectiveness analysis/12. 
cost minimization analysis/13. 
cost utility analysis/14. 
economic evaluation/15. 
(cost or costs or costed or costly or costing).tw.16. 
(economic$or pharmacoeconomic$or price$or 17. 
pricing).tw.
(technology adj assessment$).tw.18. 
or/11–1819. 
10 and 1920. 
Database: EMBASE, 1980 
to 2007, week 03
Search strategy
exp Respiratory Syncytial Pneumovirus/or rsv.1. 
mp. or exp Bronchiolitis/
bronchiolitis.mp.2. 
respiratory syncytial virus.mp.3. 
or/1–34. 
quality of life.mp. or exp ‘Quality of Life’/5. 
health status.mp. or exp Health Status/6. 
or/5–67. 
4 and 78. 
lung transplant$.mp.9. 
8 not 910. 
Cochrane Library (Wiley 
internet version), 2007, Issue 1
Search terms
respiratory next syncytial#1 
rsv#2 
bronchiolitis#3 
MeSH descriptor Bronchiolitis, Viral, this #4 
term only
MeSH descriptor Respiratory Syncytial Virus, #5 
Human, this term only
(#1 OR #2 OR #3 OR #4 OR #5)#6 
immunoprophylaxis#7 
monoclonal next antibod*#8 
MeSH descriptor Antibodies, Monoclonal #9 
explode all trees
palivizumab#10 
(#7 OR #8 OR #9 OR #10)#11 
(#6 AND #11)#12 
Office of Health Economics 
HEED database, January 2006
Search terms
RSV or respiratory syncytial virus or bronchiolitis
palivizumab or synagis or immunoprophylaxis or 
monoclonal antibod*
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Database: Ovid MEDLINE(R), 
1950 to January, week 2, 2007
Search strategy
exp Respiratory Syncytial Virus, Human/or rsv.1. 
mp.
respiratory syncytial virus.mp.2. 
bronchiolitis.mp. or exp Bronchiolitis, Viral/3. 
or/1–34. 
prognosis.mp. or exp Prognosis/5. 
outcome$.mp.6. 
risk$.mp. or exp Risk Factors/7. 
hospitali?ation.mp.8. 
exp Follow-Up Studies/or follow-up.mp.9. 
complication$.mp.10. 
exp Cohort Studies/or cohort$.mp.11. 
or/5–1012. 
11 and 1313. 
Appendix 3  
Search strategies – prognosis
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Database: Ovid MEDLINE(R), 
1950 to January, week 2, 2007
Search strategy
exp Respiratory Syncytial Virus, Human/or rsv.1. 
mp.
respiratory syncytial virus.mp.2. 
bronchiolitis.mp. or exp Bronchiolitis, Viral/3. 
or/1–34. 
prognosis.mp. or exp Prognosis/5. 
outcome$.mp.6. 
risk$.mp. or exp Risk Factors/7. 
hospitali?ation.mp.8. 
exp Follow-Up Studies/or follow-up.mp.9. 
complication$.mp.10. 
exp Cohort Studies/or cohort$.mp.11. 
or/5–1012. 
4 and 1213. 
11 and 1314. 
Appendix 4  
Search strategies – RSV hospitalisation
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Appendix 5  
Characteristics of excluded studies
TABLE 43 Excluded clinical effectiveness studies
Reference Reason for exclusion
Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter J, Aebi C. Low 
incidence of respiratory syncytial virus hospitalisations in haemodynamically significant 
congenital heart disease. Arch Dis Child 2004;89:961–5
Cohort study (neither RCT nor 
systematic review)
Fenton C, Scott LI, Plosker GL. Palivizumab: a review of its use as prophylaxis for serious 
respiratnnory syncytial virus infection. Pediatr Drugs 2004;6:177–97
Narrative review
Groothuis JR, Groothuis JR. Safety and tolerance of palivizumab administration in a large 
Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. 
Pediatr Infect Dis J 2001;20:628–30
Open label palivizumab study 
(neither RCT nor systematic 
review)
Groothuis JR, Nishida H. Prevention of respiratory syncytial virus infections in high-risk 
infants by monoclonal antibody (palivizumab). Pediatr Int 2002;44:235–41
Narrative review
Groothuis JR, Groothuis JR. Safety of palivizumab in preterm infants 29 to 32 weeks’ 
gestational age without chronic lung disease to prevent serious respiratory syncytial virus 
infection. Eur J Clin Microbiol Infect Dis 2003;22:414–17
Open label palivizumab  study 
(neither RCT nor systematic 
review)
Health Care Insurance Board. Passive immunization against RSV-infections in too early 
born children – primary research. Diemen: Health Care Insurance Board / College voor 
zorgverzekeringen (CVZ); 2005
Cost-effectiveness study
Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, et al. A direct comparison 
of the activities of two humanized respiratory syncytial virus monoclonal antibodies: 
MEDI-493 and RSHZ19. J Infect Dis 1999;180:35–40
Animal study
Korbal P, Mikolajczak A, Szymaski W, Korbal P, Mikolajczak A, Szymaski W. [Effectiveness 
of passive immunisation against respiratory syncytium virus in a group of premature 
infants with birth weight below 1000 grams]. [in Polish]. Ginekol Pol 2003;74:1154–9
Neither RCT nor systematic 
review
Lenney W, Connor E. Humanised monoclonal antibody to respiratory syncytial virus 
(MEDI-493) significantly reduces the incidence of RSV hospitalisation in at-risk infants 
[abstract]. Eur Respir J Suppl 1998;12 (Suppl 28):270S
Abstract duplicating information 
in IMpact-RSV Study Group 1998
Null D Jr, Pollara B, Dennehy PH, Steichen J, Sanchez PJ, Givner LB, et al. Safety and 
immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 
2005;24:1021–3
55/86 participants in IMpact-
RSV Study Group 1998 received 
palivizumab in second season. 
Saez-Llorens X, Moreno MT, Ramilo O, Sanchez PJ, Top FH, Jr., Connor EM, et al. Safety 
and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory 
syncytial virus infection. Pediatr Infect Dis J 2004;23:707–712
Phase I/II placebo controlled RCT 
in children hospitalised with RSV
Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, et al. Safety, 
tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory 
syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-
493 Study Group. Pediatr Infect Dis J 1998;17:110–15
Phase I/II multicentre double-
blind randomised trial, but drug 
was administrated intravenously 
not via intramuscular injections.
Wu SY, Bonaparte J, Pyati S, Wu SY, Bonaparte J, Pyati S. Palivizumab use in very 
premature infants in the neonatal intensive care unit. [see comment] Pediatrics 
2004;114:e554–e556
Not RCT
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TABLE 44 Excluded cost-effectiveness studies
Reference Reasons for exclusion
Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, et al. Intravenous 
ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after 
lung transplantation. J Heart Lung Transplant 2005;24:2114–19
Not for comparing palivizumab 
and no prophylaxis
Harkensee C, Brodlie M, Embleton ND, Mckean M. Passive immunisation of preterm 
infants with palivizumab against RSV infection. J Infect 2006;52:2–8
No relevant data
Hashmi NA, Cosgrove JF, MacMahon P, Hashmi NA, Cosgrove JF, MacMahon P. Prophylaxis 
in RSV infection (Palivizumab) – is it worthwhile? Irish Med J 2000;93:284
No relevant data
Klassen TP, Klassen TP. Economic evaluations of immunoprophylaxis in infants at high risk 
for respiratory syncytial virus: shedding light or creating confusion? [comment] Arch Pediatr 
Adolesc Med 2002;156:1180–1
No relevant data
Macartney KK, Gorelick MH, Manning ML, Hodinka RL, Bell LM, Macartney KK, et al. 
Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost–benefit of 
infection control. Pediatrics 2000;106:520–6
Not for comparing palivizumab 
and no prophylaxis
Marchetti A, Lau H, Magar R, Wang L, Devercelli G, Marchetti A, et al. Impact of 
palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: 
potential for savings. Clin Ther 1999;21:752–66
Neither CEA nor CUA nor CBA
Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH, Schrand LM, et al. A cost–benefit 
analysis of RSV prophylaxis in high-risk infants. [see comment] Ann Pharmacother 
2001;35:1186–93
Not for comparing palivizumab 
and no prophylaxis
Storch GA. Humanized monoclonal antibody for prevention of respiratory syncytial virus 
infection. Pediatrics 1998;102:648–51
No relevant data
Sze LL, Etches P, Robinson JL. Net cost of palivizumab for respiratory syncytial virus 
prophylaxis during the 1998/99 season in northern Alberta. Paediatr Child Hlth 2001;6:525–
32
No relevant data 
Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm 
infants: implications for use of RSV immunoglobulin. Arch Dis Child 2000;83:122–7
Neither CEA nor CUA nor CBA
Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, et al. Direct cost analyses of 
palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina 
Medicaid Program. Pediatrics 2004;114:1612–19
Neither CEA nor CUA nor CBA
Wills S, Simpson JH, Coutts J. Cost minimisation of RSV prevention with palivizumab. Arch 
Dis Child 2006;91:717
No relevant data
CEA, cost-effectiveness analysis; CBA, cost–benefit analysis; CUA, cost–utility analysis.
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Appendix 6  
Quality assessment of systematic reviews
A
p
p
en
dix 6
7
4
TABLE 45 Quality assessment of systematic reviews of cost-effectiveness
Author Country
Search 
method 
reported?
Comprehensive 
search?
Inclusion 
criteria 
reported?
Selection 
bias 
avoided?
Validity 
criteria 
reported?
Validity for each 
study assessed 
appropriately? 
Combining 
method 
reported?
Findings 
combined 
appropriately?
Conclusion 
supported 
by data?
Dunfield and 
Mierzwinski-
Urban, 200717
Canada Yes Yes Partially Cannot tell Partially No No Partially Yes
Embleton et 
al., 200520
UK Yes Yes Yes Yes No No No Partially Yes
Kamal et al., 
200232 
USA Yes Partially Yes Partially No No No Partially Yes
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Appendix 7  
Quality assessment of  
included RCTs for clinical effectiveness
TABLE 46 Quality assessment of included RCTs for clinical effectiveness
Study Randomised?
Concealment of 
randomisation Blinded
Intention-to-
treat analysis
Loss to follow-
up reported?
Jadad 
score
The IMpact-RSV 
Study Group, 
1998a16
Yes Yes, central interactive 
voice system
Yes Yes Yes, 99% in each 
arm completed 
follow-up
5
Feltes et al., 200312 Yes Yes, central interactive 
voice system
Yes Yes Yes, 95.6% of 
palivizumab and 
95.5% of placebo 
group completed 
the study
5
a Also reported in Lenney, 199877
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Appendix 8  
Quality assessment of  
included primary studies for cost-effectiveness
A
p
p
en
dix 8
7
8
TABLE 47 Quality assessment of included primary studies for cost-effectiveness
Author Country
Well-
defined 
question?
Description 
of 
competing 
alternatives 
given?
Effectiveness 
established?
Relevant 
costs and 
consequences 
identified?
Costs and 
consequences 
measured 
accurately?
Costs and 
consequences 
valued 
credibly?
Costs and 
consequences 
adjusted for 
differential 
timing?
Incremental 
analysis of 
cost and 
consequences 
performed?
Uncertainty 
of costs and 
consequences 
considered?
Results 
clearly 
presented 
and 
discussed?
Farina et 
al., 200233
Argentina Yes Partially Yes Yes Partially Partially Cannot tell Yes Partially Partially
Numa, 
200034
Australia Yes No Yes No Yes No Cannot tell Yes Partially Partially
Reeve et 
al., 200635
Australia Yes Partially Yes No Cannot tell Partially Cannot tell Yes No Partially
Roeckl-
Wiedmann 
et al., 
200336
Germany Yes Yes Yes Yes Yes Yes No Yes Partially Yes
Chiroli, 
200537
Italy Yes Yes Yes Yes No Partially Yes Yes Partially Yes
Vogel et al., 
200238 
New 
Zealand
Yes Yes Yes Yes Yes Yes Cannot tell Yes Partially
De 
Armentia, 
200339
Spain Yes Yes Yes Yes Yes Yes Not 
applicable
Yes No Yes
Lázaro et 
al., 200640
Spain Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Raya et al., 
200618
Spain Yes Yes Yes Yes Yes Yes Not 
applicable
Yes Yes Yes
H
ealth
 Tech
n
ology A
ssessm
en
t 2
0
0
8
; V
o
l. 1
2
: N
o
. 3
6
©
 Q
ueen’s P
rinter and
 C
o
ntro
ller o
f H
M
SO
 2
0
0
8
. A
ll righ
ts reserved
.
7
9
Author Country
Well-
defined 
question?
Description 
of 
competing 
alternatives 
given?
Effectiveness 
established?
Relevant 
costs and 
consequences 
identified?
Costs and 
consequences 
measured 
accurately?
Costs and 
consequences 
valued 
credibly?
Costs and 
consequences 
adjusted for 
differential 
timing?
Incremental 
analysis of 
cost and 
consequences 
performed?
Uncertainty 
of costs and 
consequences 
considered?
Results 
clearly 
presented 
and 
discussed?
Simpson 
and Burls, 
20019
UK Yes Yes Yes Yes Yes Yes Yes Yes Partially Partially
Nuijten et 
al., 200725
UK Yes Yes Yes Yes No Yes Yes Yes Yes Partially
Joffe, 
199941
USA Yes Yes Yes Yes Yes Yes Yes Yes Partially Yes
Lofland et 
al., 200042 
USA Yes Yes Yes Partially Partially Partially Cannot tell Yes Partially Partially
Stevens et 
al., 200043
USA Yes Partially Yes Partially Yes Partially Cannot tell Yes Partially Partially
Shireman 
and 
Braman, 
200244
USA Yes Yes Yes Partially Yes Cannot tell Cannot tell No No Yes
Strutton 
and Stang, 
200345 
USA Yes Partially Partially Yes Cannot tell Cannot tell Yes Yes No Partially
Yount et 
al., 200446
USA Yes Yes Yes Yes Yes Yes Yes Yes Partially Yes
ElHassan et 
al., 200647
USA Yes Yes Yes Yes Yes Yes Yes Yes Partially Partially
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Appendix 9  
Parameter values and their distributions  
used in the probabilistic sensitivity analysis
TABLE 48 Parameter distributions for preterm infants without CLD
Beta distributions
Parameter Expected value α β
Probability of RSV hospitalisation (no prophylaxis) 0.081 344.384 3934.08
Mortality rate of RSV hospitalisation 0.0043 17.221 3982.226
Utility of RSV hospitalisation 0.88 702.101 95.770
Utility of non-RSV hospitalisation 0.95 976.417 51.397
Probability of ICU stay 0.107 26.270 219.218
Uniform distributions
Parameter Expected value a b
Dose of palivizumab 5 4 6
Period of morbidity due to RSV 5 2 8
Normal distributions
Parameter Mean SD
Log relative risk of RSV hospitalisation –1.5404 0.0771
Length of ICU stay 1.370 0.259
Length of general ward stay 6.470 0.644
Life expectancy 77.80 11.83
CLD, chronic lung disease; ICU, intensive care unit; RSV, respiratory syncytial virus; SD, standard deviation.
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TABLE 49 Parameter distributions for preterm infants with CLD
Beta distributions
Parameter Expected value α β
Probability of RSV hospitalisation (no prophylaxis) 0.128 573.974 3900.294
Utility of RSV hospitalisation 0.88 702.101 95.770
Utility of non-RSV hospitalisation 0.95 976.417 51.397
Probability of ICU sstay 0.107 26.270 219.218
Uniform distributions
Parameter Expected value a b
Dose of palivizumab 5 4 6
Period of morbidity due to RSV 5 2 8
Mortality rate of RSV hospitalisation 0.04 0.03 0.05
Normal distributions
Parameter Mean SD
Log relative risk of RSV hospitalisation –0.4826 0.0253
Length of ICU stay 1.370 0.259
Length of general ward stay 6.470 0.644
Life expectancy 77.80 11.83
CLD, chronic lung disease; ICU, intensive care unit; RSV, respiratory syncytial virus; SD, standard deviation.
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TABLE 50 Parameter distributions for CHD
Beta distributions
Parameter Expected value α β
Probability of RSV hospitalisation (no prophylaxis) 0.097 21.895 203.830
Mortality rate of RSV hospitalisation 0.0372 8.012 207.920
Utility of RSV hospitalisation 0.88 702.101 95.770
Utility of non-RSV hospitalisation 0.95 976.417 51.397
Probability of ICU stay 0.387 123.685 195.916
Uniform distributions
Parameter Expected value a b
Dose of palivizumab 5 4 6
Period of morbidity due to RSV 5 2 8
Normal distributions
Parameter Mean SD
Log relative risk of RSV hospitalisation –0.603 0.042
Length of ICU stay 6.14 1.009
Length of general ward stay 6.25 0.635
Life expectancy 77.11 11.83
CLD, chronic lung disease; ICU, intensive care unit; RSV, respiratory syncytial virus; SD, standard deviation.
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Appendix 10  
Probability of hospitalisation for  
RSV infection of no prophylaxis  
in children with or without CLD or CHD
TABLE 51 Probability of hospitalisation for RSV infection of no prophylaxis in children without CLD
Gestational age (weeks)
Birth age (months) ≤ 24 24–26 26–28 28–30 30–32 32–34
<3 0.29 0.23 0.17 0.13 0.10 0.07
3–6 0.17 0.13 0.10 0.07 0.05 0.04
6–9 0.10 0.07 0.05 0.04 0.03 0.02
9–12 0.05 0.04 0.03 0.02 0.01 0.01
12–15 0.03 0.02 0.01 0.01 0.01 0.01
15–18 0.01 0.01 0.01 0.01 0.00 0.00
18–21 0.01 0.01 0.00 0.00 0.00 0.00
21–24 0.00 0.00 0.00 0.00 0.00 0.00
CLD, chronic lung disease; RSV, respiratory syncytial virus.
TABLE 52 Probability of hospitalisation for RSV infection of no prophylaxis in children with CLD 
Gestational age (weeks)
Birth age (months) ≤฀24 24–26 26–28 28–30 30–32 32–34
<3 0.55 0.47 0.39 0.32 0.25 0.20
3–6 0.39 0.32 0.25 0.19 0.15 0.11
6–9 0.25 0.19 0.15 0.11 0.08 0.06
9–12 0.14 0.11 0.08 0.06 0.04 0.03
12–15 0.08 0.06 0.04 0.03 0.02 0.02
15–18 0.04 0.03 0.02 0.02 0.01 0.01
18–21 0.02 0.02 0.01 0.01 0.01 0.00
21–24 0.01 0.01 0.01 0.00 0.00 0.00
CLD, chronic lung disease; RSV, respiratory syncytial virus.
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TABLE 53 Probability of hospitalisation for RSV infection of no prophylaxis in children with siblings in day-care groups
Gestational age (weeks)
Birth age (months) ≤ 24 24–26 26–28 28–30 30–32 32–34
<3 0.43 0.35 0.28 0.22 0.17 0.13
3–6 0.28 0.22 0.17 0.13 0.09 0.07
6–9 0.16 0.12 0.09 0.07 0.05 0.04
9–12 0.09 0.07 0.05 0.04 0.03 0.02
12–15 0.05 0.04 0.03 0.02 0.01 0.01
15–18 0.03 0.02 0.01 0.01 0.01 0.01
18–21 0.01 0.01 0.01 0.01 0.00 0.00
21–24 0.01 0.00 0.00 0.00 0.00 0.00
RSV, respiratory syncytial virus.
TABLE 54 Probability of hospitalisation for RSV infection of no prophylaxis in children with CLD and with siblings in day-care groups
Gestational age (weeks)
Birth age (months) ≤฀24 24–26 26–28 28–30 30–32 32–34
<3 0.70 0.62 0.55 0.47 0.39 0.31
3–6 0.54 0.46 0.38 0.31 0.24 0.19
6–9 0.38 0.31 0.24 0.19 0.14 0.11
9–12 0.24 0.18 0.14 0.11 0.08 0.06
12–15 0.14 0.10 0.08 0.06 0.04 0.03
15–18 0.08 0.06 0.04 0.03 0.02 0.02
18–21 0.04 0.03 0.02 0.02 0.01 0.01
21–24 0.02 0.02 0.01 0.01 0.01 0.00
CLD, chronic lung disease; RSV, respiratory syncytial virus.
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